###begin article-title 0
###xml 19 24 <span type="species:ncbi:9606">human</span>
Peroxiredoxin 6 in human brain: molecular forms, cellular distribution and association with Alzheimer's disease pathology
###end article-title 0
###begin p 1
###xml 196 201 <span type="species:ncbi:9606">human</span>
###xml 230 237 <span type="species:ncbi:9606">patient</span>
###xml 1396 1404 <span type="species:ncbi:9606">patients</span>
###xml 1656 1661 <span type="species:ncbi:9606">human</span>
Peroxiredoxin 6 is an antioxidant enzyme and is the 1-cys member of the peroxiredoxin family. Using two-dimensional electrophoresis and Western blotting, we have shown for the first time that, in human control and brain tissue of patient's with Alzheimer's disease (AD), this enzyme exists as three major and five minor forms with pIs from 5.3 to 6.1. Using specific cellular markers, we have shown that peroxiredoxin 6 is present in astrocytes with very low levels in neurons, but not detectable in microglia or oligodendrocytes. In control brains, there was a very low level of peroxiredoxin 6 staining in astrocytes that was confined to a "halo" around the nucleus. In AD, there were marked increases in the number and staining intensity of peroxiredoxin 6 positive astrocytes in both gray and white matter in the midfrontal cortex, cingulate, hippocampus and amygdala. Confocal microscopy using antibodies to Abeta peptide, tau and peroxiredoxin 6 showed that peroxiredoxin 6 positive astrocytes are closely involved with diffuse plaques and to a lesser extent with neuritic plaques, suggesting that plaques are producing reactive oxygen species. There appeared to be little astrocytic response to tau containing neurons. Although peroxiredoxin 6 positive astrocytes were seen to make multiple contacts with tau positive neurons, there was no intraneuronal colocalization. In brain tissue of patients with AD, many blood vessels exhibited peroxiredoxin 6 staining that appeared to be due to the astrocytic foot processes. These results suggest that oxidative stress conditions exist in AD and that peroxiredoxin 6 is an important antioxidant enzyme in human brain defenses.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 614 616 611 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 798 800 795 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 982 984 979 981 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">26</xref>
###xml 1154 1155 1145 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 1157 1158 1148 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">6</xref>
###xml 1217 1219 1208 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 1338 1339 1326 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 1395 1396 1383 1384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">7</xref>
###xml 1508 1510 1496 1498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the progressive decline in memory, language, cognition and motor functions. The neuropathological hallmarks of AD are the accumulation of extracellular amyloid plaques containing the amyloid beta peptide (Abeta) and intraneuronal neurofibrillary tangles containing hyperphosphorylated microtubule-associated protein tau. Although the initiating molecular event(s) in AD are not known, oxidative stress produced by the generation of reactive oxygen species (ROS) appears to be a fundamental process contributing to the neuropathophysiology [10]. Whether oxidative stress has a role in the cause or affect in AD has been debated for many years, but recent research has suggested that it occurs prior to the onset of symptoms [35]. The histopathological evidence for oxidative stress in AD includes lipid, protein and DNA oxidation. There is evidence to suggest that oxidative stress is generated peripherally [26] with the brain being particularly susceptible, but there is also a body of evidence to suggest that amyloid beta peptide (Abeta42) may be linked to lipid peroxidation [5, 6], which may then be linked to the phosphorylation of tau [24]. Two reactive products of Abeta42-induced lipid peroxidation are the production of four hydroxynonenal and acrolein [5], which have been shown to disrupt membrane asymmetry [7] and may be involved in the conformational changes to tau, promoting the formation of neurofibrillary tangles [24].
###end p 4
###begin p 5
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 240 241 240 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 833 834 833 834 <sub xmlns:xlink="http://www.w3.org/1999/xlink">,</sub>
Oxidative damage occurs as part of the aging process, but it occurs at a much greater rate in most neurodegenerative diseases [3]. The hallmark of protein oxidation is the generation of protein carbonyls, which are markedly elevated in AD [3, 16]. There is overwhelming evidence to implicate oxidative stress in the pathogenesis of AD, and this is most likely an early event in the disease process. Less is known however of how the brain responds to oxidative insults. There are a number of cellular antioxidant defenses whose primary role is to convert the ROS into unreactive compounds. These defense mechanisms include superoxide dismutase, which works together with selenium-dependent glutathione peroxidase, catalase and more recently the peroxiredoxin family. These enzymes transform the superoxide radical to hydrogen peroxide, which in turn is converted to water. The distribution and changes in expression of the antioxidant enzymes have not been well studied as the other aspects of the disease process.
###end p 5
###begin p 6
###xml 296 298 296 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 381 382 381 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 384 386 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 612 613 609 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
Cellular selenium-dependant glutathione peroxidase (GPx-1) has long been regarded as the major cellular antioxidant enzyme, but there are conflicting reports regarding the changes in activities of this enzyme in AD. Early reports suggest that there is no change in GPx-1 activities in AD brains [15, 20], while other researchers suggest that there is a decrease in GPx-1 activity [8, 27, 32]. There are no reports indicating compensatory increase in GPx-1 activity; however, cell models overexpressing GPx-1 are more resistant to Abeta-mediated toxicity, suggesting that increased levels of GPx-1 is protective [2].
###end p 6
###begin p 7
###xml 343 345 340 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 535 536 532 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
There is considerable evidence to implicate Abeta toxicity and the generation of ROS and in particular hydrogen peroxide as key steps in contributing to the neurotoxicity in AD. We have previously reported that peroxiredoxin 6, also termed 1 Cys-peroxiredoxin or nonselenium glutathione peroxidase, is upregulated in Parkinson's disease (PD) [30]. This enzyme has no amino acid homology to any known sequence of the glutathione peroxidase enzymes and has both antioxidant and phospholipase A2 activity and can reduce hydroxyperoxides [9]. Given that the brain is particularly vulnerable to oxidative damage due to its high energy and oxygen requirements, high levels of transition metals and peroxidizable fatty acids suggests that peroxiredoxin 6 could play a key antioxidant role in neuroprotection.
###end p 7
###begin p 8
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 348 356 <span type="species:ncbi:9606">patients</span>
There are six members of the peroxiredoxin family at this stage with peroxiredoxins 1-5 being the 2-Cys members while peroxiredoxin 6 is the sole 1-Cys member [36]. This enzyme is bifunctional with 80% of its function as a peroxidase and the remainder as a phospholipase A2. Peroxiredoxin 6 has not specifically been examined in brain tissue of AD patients, and the aims of this study are to examine the molecular forms, cellular distribution and association with AD pathology. This study focused on the cingulate, amygdala, hippocampus and cortical regions in six AD and six control brains.
###end p 8
###begin title 9
Materials and methods
###end title 9
###begin title 10
Antibodies
###end title 10
###begin title 11
Primary antibodies
###end title 11
###begin p 12
###xml 17 23 <span type="species:ncbi:9986">rabbit</span>
###xml 109 114 <span type="species:ncbi:10090">mouse</span>
###xml 183 187 <span type="species:ncbi:9925">goat</span>
###xml 269 274 <span type="species:ncbi:10090">mouse</span>
###xml 378 383 <span type="species:ncbi:10090">mouse</span>
###xml 447 452 <span type="species:ncbi:9606">Human</span>
###xml 479 484 <span type="species:ncbi:10090">mouse</span>
###xml 540 545 <span type="species:ncbi:9606">Human</span>
###xml 558 563 <span type="species:ncbi:10090">mouse</span>
###xml 640 645 <span type="species:ncbi:10090">mouse</span>
Peroxiredoxin 6 (rabbit) was obtained from Antibody Technology Australia Pty, Ltd, Adelaide, Australia. Tau (mouse) was obtained from Novacastra Laboratories Ltd, Newcastle, UK. Tau (goat) was obtained from Santa Cruz Biotechnology Inc., California, USA. Amyloid beta (mouse) was obtained from Novacastra Laboratories Ltd, Newcastle, UK. Glial fibrillary acidic protein (GFAP) (mouse) was obtained from Novacastra Laboratories Ltd, Newcastle, UK. Human neuronal protein HuC/HuD (mouse) was obtained from Molecular Probes Inc., Eugene, USA. Human HLA (MHC2) (mouse) was obtained from Dakocytomation, Denmark A/S. Myelin basic protein (MBP) (mouse) was obtained from Novacastra Laboratories Ltd, Newcastle, UK.
###end p 12
###begin title 13
Secondary antibodies
###end title 13
###begin p 14
###xml 0 6 <span type="species:ncbi:9793">Donkey</span>
###xml 12 17 <span type="species:ncbi:9940">sheep</span>
###xml 81 87 <span type="species:ncbi:9793">Donkey</span>
###xml 171 175 <span type="species:ncbi:9925">Goat</span>
###xml 250 254 <span type="species:ncbi:9925">Goat</span>
Donkey anti sheep Cy3 was obtained from Jackson Immunoresearch, West Grove, USA. Donkey antirabbit Cy3 and Cy5 were obtained from Jackson Immunoresearch, West Grove, USA. Goat antimouse Alexa 488 was obtained from Molecular Probes Inc., Eugene, USA. Goat antirabbit alkaline phosphatase was obtained from Sigma Chemical Company, St Louis, USA.
###end p 14
###begin title 15
Brain tissue
###end title 15
###begin p 16
###xml 614 615 607 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 684 691 677 684 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 691 726 684 719 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="17">List of cases used in cell counting</p>
###xml 691 726 684 719 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="17">List of cases used in cell counting</p></caption>
###xml 726 737 719 730 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case number</th>
###xml 737 740 730 733 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Sex</th>
###xml 740 751 733 744 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Age (years)</th>
###xml 751 760 744 753 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Diagnosis</th>
###xml 760 766 753 759 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Region</th>
###xml 766 773 759 766 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PMI (h)</th>
###xml 773 784 766 777 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Braak stage</th>
###xml 784 794 777 787 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NIA Reagan</th>
###xml 726 794 719 787 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Case number</th><th align="left">Sex</th><th align="left">Age (years)</th><th align="left">Diagnosis</th><th align="left">Region</th><th align="left">PMI (h)</th><th align="left">Braak stage</th><th align="left">NIA Reagan</th></tr>
###xml 726 794 719 787 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Case number</th><th align="left">Sex</th><th align="left">Age (years)</th><th align="left">Diagnosis</th><th align="left">Region</th><th align="left">PMI (h)</th><th align="left">Braak stage</th><th align="left">NIA Reagan</th></tr></thead>
###xml 794 797 787 790 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD1</td>
###xml 797 798 790 791 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M</td>
###xml 798 800 791 793 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">65</td>
###xml 800 802 793 795 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD</td>
###xml 802 814 795 807 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C, A, H, MC </td>
###xml 814 815 807 808 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 815 818 808 811 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5/6</td>
###xml 818 822 811 815 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">High</td>
###xml 794 822 787 815 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD1</td><td align="left">M</td><td char="." align="char">65</td><td align="left">AD</td><td align="left">C, A, H, MC </td><td char="." align="char">3</td><td align="left">5/6</td><td align="left">High</td></tr>
###xml 822 825 815 818 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD2</td>
###xml 825 826 818 819 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 826 828 819 821 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">84</td>
###xml 828 830 821 823 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD</td>
###xml 830 842 823 835 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C, A, H, MC </td>
###xml 842 844 835 837 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">16</td>
###xml 844 847 837 840 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5/6</td>
###xml 847 851 840 844 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">High</td>
###xml 822 851 815 844 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD2</td><td align="left">F</td><td char="." align="char">84</td><td align="left">AD</td><td align="left">C, A, H, MC </td><td char="." align="char">16</td><td align="left">5/6</td><td align="left">High</td></tr>
###xml 851 854 844 847 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD3</td>
###xml 854 855 847 848 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M</td>
###xml 855 857 848 850 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">63</td>
###xml 857 859 850 852 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD</td>
###xml 859 871 852 864 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C, A, H, MC </td>
###xml 871 873 864 866 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">33</td>
###xml 873 876 866 869 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5/6</td>
###xml 876 880 869 873 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">High</td>
###xml 851 880 844 873 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD3</td><td align="left">M</td><td char="." align="char">63</td><td align="left">AD</td><td align="left">C, A, H, MC </td><td char="." align="char">33</td><td align="left">5/6</td><td align="left">High</td></tr>
###xml 880 883 873 876 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD4</td>
###xml 883 884 876 877 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M</td>
###xml 884 886 877 879 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">59</td>
###xml 886 888 879 881 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD</td>
###xml 888 899 881 892 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C, A, H, MC</td>
###xml 899 901 892 894 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">20</td>
###xml 901 904 894 897 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5/6</td>
###xml 904 908 897 901 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">High</td>
###xml 880 908 873 901 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD4</td><td align="left">M</td><td char="." align="char">59</td><td align="left">AD</td><td align="left">C, A, H, MC</td><td char="." align="char">20</td><td align="left">5/6</td><td align="left">High</td></tr>
###xml 908 911 901 904 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD5</td>
###xml 911 912 904 905 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 912 914 905 907 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">81</td>
###xml 914 916 907 909 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD</td>
###xml 916 927 909 920 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C, A, H, MC</td>
###xml 927 929 920 922 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">19</td>
###xml 929 932 922 925 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5/6</td>
###xml 932 936 925 929 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">High</td>
###xml 908 936 901 929 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD5</td><td align="left">F</td><td char="." align="char">81</td><td align="left">AD</td><td align="left">C, A, H, MC</td><td char="." align="char">19</td><td align="left">5/6</td><td align="left">High</td></tr>
###xml 936 939 929 932 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD6</td>
###xml 939 940 932 933 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 940 942 933 935 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">69</td>
###xml 942 944 935 937 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD</td>
###xml 944 955 937 948 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C, A, H, MC</td>
###xml 955 957 948 950 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">38</td>
###xml 957 960 950 953 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5/6</td>
###xml 960 964 953 957 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">High</td>
###xml 936 964 929 957 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD6</td><td align="left">F</td><td char="." align="char">69</td><td align="left">AD</td><td align="left">C, A, H, MC</td><td char="." align="char">38</td><td align="left">5/6</td><td align="left">High</td></tr>
###xml 964 966 957 959 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C1</td>
###xml 966 967 959 960 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 967 969 960 962 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">79</td>
###xml 969 972 962 965 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ADL</td>
###xml 972 983 965 976 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C, A, H, MC</td>
###xml 983 984 976 977 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4</td>
###xml 984 984 977 977 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 984 987 977 980 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Low</td>
###xml 964 987 957 980 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">C1</td><td align="left">F</td><td char="." align="char">79</td><td align="left">ADL</td><td align="left">C, A, H, MC</td><td char="." align="char">4</td><td align="left"/><td align="left">Low</td></tr>
###xml 987 989 980 982 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C2</td>
###xml 989 990 982 983 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M</td>
###xml 990 992 983 985 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">69</td>
###xml 992 995 985 988 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Unk</td>
###xml 995 1006 988 999 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C, A, H, MC</td>
###xml 1006 1008 999 1001 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">48</td>
###xml 1008 1008 1001 1001 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1008 1011 1001 1004 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Low</td>
###xml 987 1011 980 1004 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">C2</td><td align="left">M</td><td char="." align="char">69</td><td align="left">Unk</td><td align="left">C, A, H, MC</td><td char="." align="char">48</td><td align="left"/><td align="left">Low</td></tr>
###xml 1011 1013 1004 1006 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C3</td>
###xml 1013 1014 1006 1007 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 1014 1016 1007 1009 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">61</td>
###xml 1016 1018 1009 1011 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CF</td>
###xml 1018 1029 1011 1022 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C, A, H, MC</td>
###xml 1029 1030 1022 1023 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">8</td>
###xml 1030 1030 1023 1023 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1030 1033 1023 1026 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Low</td>
###xml 1011 1033 1004 1026 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">C3</td><td align="left">F</td><td char="." align="char">61</td><td align="left">CF</td><td align="left">C, A, H, MC</td><td char="." align="char">8</td><td align="left"/><td align="left">Low</td></tr>
###xml 1033 1035 1026 1028 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C4</td>
###xml 1035 1036 1028 1029 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 1036 1038 1029 1031 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">84</td>
###xml 1038 1040 1031 1033 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">SS</td>
###xml 1040 1051 1033 1044 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C, A, H, MC</td>
###xml 1051 1053 1044 1046 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">15</td>
###xml 1053 1053 1046 1046 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1053 1056 1046 1049 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Low</td>
###xml 1033 1056 1026 1049 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">C4</td><td align="left">F</td><td char="." align="char">84</td><td align="left">SS</td><td align="left">C, A, H, MC</td><td char="." align="char">15</td><td align="left"/><td align="left">Low</td></tr>
###xml 1056 1058 1049 1051 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C5</td>
###xml 1058 1059 1051 1052 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 1059 1061 1052 1054 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">86</td>
###xml 1061 1063 1054 1056 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">DM</td>
###xml 1063 1074 1056 1067 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C, A, H, MC</td>
###xml 1074 1076 1067 1069 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">17</td>
###xml 1076 1076 1069 1069 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1076 1079 1069 1072 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Low</td>
###xml 1056 1079 1049 1072 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">C5</td><td align="left">F</td><td char="." align="char">86</td><td align="left">DM</td><td align="left">C, A, H, MC</td><td char="." align="char">17</td><td align="left"/><td align="left">Low</td></tr>
###xml 1079 1081 1072 1074 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C6</td>
###xml 1081 1082 1074 1075 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 1082 1084 1075 1077 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">86</td>
###xml 1084 1087 1077 1080 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HVD</td>
###xml 1087 1098 1080 1091 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C, A, H, MC</td>
###xml 1098 1099 1091 1092 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 1099 1099 1092 1092 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 1099 1102 1092 1095 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Low</td>
###xml 1079 1102 1072 1095 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">C6</td><td align="left">F</td><td char="." align="char">86</td><td align="left">HVD</td><td align="left">C, A, H, MC</td><td char="." align="char">6</td><td align="left"/><td align="left">Low</td></tr>
###xml 794 1102 787 1095 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">AD1</td><td align="left">M</td><td char="." align="char">65</td><td align="left">AD</td><td align="left">C, A, H, MC </td><td char="." align="char">3</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD2</td><td align="left">F</td><td char="." align="char">84</td><td align="left">AD</td><td align="left">C, A, H, MC </td><td char="." align="char">16</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD3</td><td align="left">M</td><td char="." align="char">63</td><td align="left">AD</td><td align="left">C, A, H, MC </td><td char="." align="char">33</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD4</td><td align="left">M</td><td char="." align="char">59</td><td align="left">AD</td><td align="left">C, A, H, MC</td><td char="." align="char">20</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD5</td><td align="left">F</td><td char="." align="char">81</td><td align="left">AD</td><td align="left">C, A, H, MC</td><td char="." align="char">19</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD6</td><td align="left">F</td><td char="." align="char">69</td><td align="left">AD</td><td align="left">C, A, H, MC</td><td char="." align="char">38</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">C1</td><td align="left">F</td><td char="." align="char">79</td><td align="left">ADL</td><td align="left">C, A, H, MC</td><td char="." align="char">4</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C2</td><td align="left">M</td><td char="." align="char">69</td><td align="left">Unk</td><td align="left">C, A, H, MC</td><td char="." align="char">48</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C3</td><td align="left">F</td><td char="." align="char">61</td><td align="left">CF</td><td align="left">C, A, H, MC</td><td char="." align="char">8</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C4</td><td align="left">F</td><td char="." align="char">84</td><td align="left">SS</td><td align="left">C, A, H, MC</td><td char="." align="char">15</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C5</td><td align="left">F</td><td char="." align="char">86</td><td align="left">DM</td><td align="left">C, A, H, MC</td><td char="." align="char">17</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C6</td><td align="left">F</td><td char="." align="char">86</td><td align="left">HVD</td><td align="left">C, A, H, MC</td><td char="." align="char">6</td><td align="left"/><td align="left">Low</td></tr></tbody>
###xml 726 1102 719 1095 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Case number</th><th align="left">Sex</th><th align="left">Age (years)</th><th align="left">Diagnosis</th><th align="left">Region</th><th align="left">PMI (h)</th><th align="left">Braak stage</th><th align="left">NIA Reagan</th></tr></thead><tbody><tr><td align="left">AD1</td><td align="left">M</td><td char="." align="char">65</td><td align="left">AD</td><td align="left">C, A, H, MC </td><td char="." align="char">3</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD2</td><td align="left">F</td><td char="." align="char">84</td><td align="left">AD</td><td align="left">C, A, H, MC </td><td char="." align="char">16</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD3</td><td align="left">M</td><td char="." align="char">63</td><td align="left">AD</td><td align="left">C, A, H, MC </td><td char="." align="char">33</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD4</td><td align="left">M</td><td char="." align="char">59</td><td align="left">AD</td><td align="left">C, A, H, MC</td><td char="." align="char">20</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD5</td><td align="left">F</td><td char="." align="char">81</td><td align="left">AD</td><td align="left">C, A, H, MC</td><td char="." align="char">19</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD6</td><td align="left">F</td><td char="." align="char">69</td><td align="left">AD</td><td align="left">C, A, H, MC</td><td char="." align="char">38</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">C1</td><td align="left">F</td><td char="." align="char">79</td><td align="left">ADL</td><td align="left">C, A, H, MC</td><td char="." align="char">4</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C2</td><td align="left">M</td><td char="." align="char">69</td><td align="left">Unk</td><td align="left">C, A, H, MC</td><td char="." align="char">48</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C3</td><td align="left">F</td><td char="." align="char">61</td><td align="left">CF</td><td align="left">C, A, H, MC</td><td char="." align="char">8</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C4</td><td align="left">F</td><td char="." align="char">84</td><td align="left">SS</td><td align="left">C, A, H, MC</td><td char="." align="char">15</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C5</td><td align="left">F</td><td char="." align="char">86</td><td align="left">DM</td><td align="left">C, A, H, MC</td><td char="." align="char">17</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C6</td><td align="left">F</td><td char="." align="char">86</td><td align="left">HVD</td><td align="left">C, A, H, MC</td><td char="." align="char">6</td><td align="left"/><td align="left">Low</td></tr></tbody></table>
###xml 1102 1105 1095 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PMI</italic>
###xml 1124 1126 1117 1119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AD</italic>
###xml 1148 1158 1141 1151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NIA Reagan</italic>
###xml 1188 1191 1181 1184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">, M</italic>
###xml 1198 1199 1191 1192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 1208 1209 1201 1202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1221 1222 1214 1215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1233 1234 1226 1227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1248 1250 1241 1243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MC</italic>
###xml 1270 1271 1263 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1281 1284 1274 1277 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADL</italic>
###xml 1307 1310 1300 1303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Unk</italic>
###xml 1320 1322 1313 1315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CF</italic>
###xml 1340 1342 1333 1335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SS</italic>
###xml 1357 1359 1350 1352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DM</italic>
###xml 1385 1388 1378 1381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HVD</italic>
###xml 1102 1418 1095 1411 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="18"><italic>PMI</italic> postmortem index, <italic>AD</italic> Alzheimer&#8217;s disease, <italic>NIA Reagan</italic> high or low likely-hood of AD<italic>, M</italic> male, <italic>F</italic> female, <italic>C</italic> cingulate, <italic>A</italic> amygdala, <italic>H</italic> hippocampus, <italic>MC</italic> midfrontal cortex, <italic>C</italic> control, <italic>ADL</italic> adeno lung carcinoma, <italic>Unk</italic> unknown, <italic>CF</italic> cardiac failure, <italic>SS</italic> septic shock, <italic>DM</italic> disseminated malignancy, <italic>HVD</italic> hypertensive vascular disease</p>
###xml 1102 1418 1095 1411 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="18"><italic>PMI</italic> postmortem index, <italic>AD</italic> Alzheimer&#8217;s disease, <italic>NIA Reagan</italic> high or low likely-hood of AD<italic>, M</italic> male, <italic>F</italic> female, <italic>C</italic> cingulate, <italic>A</italic> amygdala, <italic>H</italic> hippocampus, <italic>MC</italic> midfrontal cortex, <italic>C</italic> control, <italic>ADL</italic> adeno lung carcinoma, <italic>Unk</italic> unknown, <italic>CF</italic> cardiac failure, <italic>SS</italic> septic shock, <italic>DM</italic> disseminated malignancy, <italic>HVD</italic> hypertensive vascular disease</p></table-wrap-foot>
###xml 684 1418 677 1411 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="17">List of cases used in cell counting</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Case number</th><th align="left">Sex</th><th align="left">Age (years)</th><th align="left">Diagnosis</th><th align="left">Region</th><th align="left">PMI (h)</th><th align="left">Braak stage</th><th align="left">NIA Reagan</th></tr></thead><tbody><tr><td align="left">AD1</td><td align="left">M</td><td char="." align="char">65</td><td align="left">AD</td><td align="left">C, A, H, MC </td><td char="." align="char">3</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD2</td><td align="left">F</td><td char="." align="char">84</td><td align="left">AD</td><td align="left">C, A, H, MC </td><td char="." align="char">16</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD3</td><td align="left">M</td><td char="." align="char">63</td><td align="left">AD</td><td align="left">C, A, H, MC </td><td char="." align="char">33</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD4</td><td align="left">M</td><td char="." align="char">59</td><td align="left">AD</td><td align="left">C, A, H, MC</td><td char="." align="char">20</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD5</td><td align="left">F</td><td char="." align="char">81</td><td align="left">AD</td><td align="left">C, A, H, MC</td><td char="." align="char">19</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD6</td><td align="left">F</td><td char="." align="char">69</td><td align="left">AD</td><td align="left">C, A, H, MC</td><td char="." align="char">38</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">C1</td><td align="left">F</td><td char="." align="char">79</td><td align="left">ADL</td><td align="left">C, A, H, MC</td><td char="." align="char">4</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C2</td><td align="left">M</td><td char="." align="char">69</td><td align="left">Unk</td><td align="left">C, A, H, MC</td><td char="." align="char">48</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C3</td><td align="left">F</td><td char="." align="char">61</td><td align="left">CF</td><td align="left">C, A, H, MC</td><td char="." align="char">8</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C4</td><td align="left">F</td><td char="." align="char">84</td><td align="left">SS</td><td align="left">C, A, H, MC</td><td char="." align="char">15</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C5</td><td align="left">F</td><td char="." align="char">86</td><td align="left">DM</td><td align="left">C, A, H, MC</td><td char="." align="char">17</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C6</td><td align="left">F</td><td char="." align="char">86</td><td align="left">HVD</td><td align="left">C, A, H, MC</td><td char="." align="char">6</td><td align="left"/><td align="left">Low</td></tr></tbody></table><table-wrap-foot><p textid="18"><italic>PMI</italic> postmortem index, <italic>AD</italic> Alzheimer&#8217;s disease, <italic>NIA Reagan</italic> high or low likely-hood of AD<italic>, M</italic> male, <italic>F</italic> female, <italic>C</italic> cingulate, <italic>A</italic> amygdala, <italic>H</italic> hippocampus, <italic>MC</italic> midfrontal cortex, <italic>C</italic> control, <italic>ADL</italic> adeno lung carcinoma, <italic>Unk</italic> unknown, <italic>CF</italic> cardiac failure, <italic>SS</italic> septic shock, <italic>DM</italic> disseminated malignancy, <italic>HVD</italic> hypertensive vascular disease</p></table-wrap-foot></table-wrap>
###xml 257 263 <span type="species:ncbi:9606">people</span>
The brain tissue was obtained from the National Health and Medical Research Council South Australian Brain Bank. Brains were removed at autopsy from clinically diagnosed AD cases and confirmed pathologically postmortem. The control cases were obtained from people who died of unrelated causes without diagnosed neurological pathology that was confirmed postmortem. The brains were bisected and one half snap-frozen at -80degreesC and the other immersion fixed in buffered formaldehyde. Tissue blocks were processed and embedded in paraffin and 8 mum sections were cut and mounted onto gelatin-coated slides. Table 1 provides a list of the brain regions examined and the case details. Table 1List of cases used in cell countingCase numberSexAge (years)DiagnosisRegionPMI (h)Braak stageNIA ReaganAD1M65ADC, A, H, MC 35/6HighAD2F84ADC, A, H, MC 165/6HighAD3M63ADC, A, H, MC 335/6HighAD4M59ADC, A, H, MC205/6HighAD5F81ADC, A, H, MC195/6HighAD6F69ADC, A, H, MC385/6HighC1F79ADLC, A, H, MC4LowC2M69UnkC, A, H, MC48LowC3F61CFC, A, H, MC8LowC4F84SSC, A, H, MC15LowC5F86DMC, A, H, MC17LowC6F86HVDC, A, H, MC6LowPMI postmortem index, AD Alzheimer's disease, NIA Reagan high or low likely-hood of AD, M male, F female, C cingulate, A amygdala, H hippocampus, MC midfrontal cortex, C control, ADL adeno lung carcinoma, Unk unknown, CF cardiac failure, SS septic shock, DM disseminated malignancy, HVD hypertensive vascular disease
###end p 16
###begin p 17
List of cases used in cell counting
###end p 17
###begin p 18
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PMI</italic>
###xml 22 24 22 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AD</italic>
###xml 46 56 46 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NIA Reagan</italic>
###xml 86 89 86 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">, M</italic>
###xml 96 97 96 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 106 107 106 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 119 120 119 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 131 132 131 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 146 148 146 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MC</italic>
###xml 168 169 168 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 179 182 179 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ADL</italic>
###xml 205 208 205 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Unk</italic>
###xml 218 220 218 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CF</italic>
###xml 238 240 238 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SS</italic>
###xml 255 257 255 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DM</italic>
###xml 283 286 283 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HVD</italic>
PMI postmortem index, AD Alzheimer's disease, NIA Reagan high or low likely-hood of AD, M male, F female, C cingulate, A amygdala, H hippocampus, MC midfrontal cortex, C control, ADL adeno lung carcinoma, Unk unknown, CF cardiac failure, SS septic shock, DM disseminated malignancy, HVD hypertensive vascular disease
###end p 18
###begin title 19
Brain homogenate
###end title 19
###begin p 20
###xml 416 417 415 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g</italic>
###xml 497 498 490 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 536 543 529 536 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 543 591 536 584 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="21">List of cases used for 2D PAGE and Western blots</p>
###xml 543 591 536 584 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="21">List of cases used for 2D PAGE and Western blots</p></caption>
###xml 591 602 584 595 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Case number</th>
###xml 602 605 595 598 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Sex</th>
###xml 605 616 598 609 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Age (years)</th>
###xml 616 625 609 618 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Diagnosis</th>
###xml 625 631 618 624 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Region</th>
###xml 631 638 624 631 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PMI (h)</th>
###xml 638 649 631 642 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Braak stage</th>
###xml 649 659 642 652 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NIA Reagan</th>
###xml 591 659 584 652 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Case number</th><th align="left">Sex</th><th align="left">Age (years)</th><th align="left">Diagnosis</th><th align="left">Region</th><th align="left">PMI (h)</th><th align="left">Braak stage</th><th align="left">NIA Reagan</th></tr>
###xml 591 659 584 652 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Case number</th><th align="left">Sex</th><th align="left">Age (years)</th><th align="left">Diagnosis</th><th align="left">Region</th><th align="left">PMI (h)</th><th align="left">Braak stage</th><th align="left">NIA Reagan</th></tr></thead>
###xml 659 662 652 655 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD7</td>
###xml 662 663 655 656 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 663 665 656 658 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">69</td>
###xml 665 667 658 660 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD</td>
###xml 667 669 660 662 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">MC</td>
###xml 669 671 662 664 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">22</td>
###xml 671 674 664 667 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5/6</td>
###xml 674 678 667 671 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">High</td>
###xml 659 678 652 671 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD7</td><td align="left">F</td><td char="." align="char">69</td><td align="left">AD</td><td align="left">MC</td><td char="." align="char">22</td><td align="left">5/6</td><td align="left">High</td></tr>
###xml 678 681 671 674 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD8</td>
###xml 681 682 674 675 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 682 684 675 677 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">79</td>
###xml 684 686 677 679 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD</td>
###xml 686 688 679 681 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">MC</td>
###xml 688 690 681 683 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">18</td>
###xml 690 693 683 686 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5/6</td>
###xml 693 697 686 690 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">High</td>
###xml 678 697 671 690 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD8</td><td align="left">F</td><td char="." align="char">79</td><td align="left">AD</td><td align="left">MC</td><td char="." align="char">18</td><td align="left">5/6</td><td align="left">High</td></tr>
###xml 697 700 690 693 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD9</td>
###xml 700 701 693 694 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 701 703 694 696 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">76</td>
###xml 703 705 696 698 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">AD</td>
###xml 705 707 698 700 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">MC</td>
###xml 707 709 700 702 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">23</td>
###xml 709 712 702 705 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5/6</td>
###xml 712 716 705 709 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">High</td>
###xml 697 716 690 709 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">AD9</td><td align="left">F</td><td char="." align="char">76</td><td align="left">AD</td><td align="left">MC</td><td char="." align="char">23</td><td align="left">5/6</td><td align="left">High</td></tr>
###xml 716 718 709 711 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C6</td>
###xml 718 719 711 712 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 719 721 712 714 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">86</td>
###xml 721 724 714 717 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HVD</td>
###xml 724 726 717 719 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">MC</td>
###xml 726 727 719 720 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 727 727 720 720 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 727 730 720 723 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Low</td>
###xml 716 730 709 723 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">C6</td><td align="left">F</td><td char="." align="char">86</td><td align="left">HVD</td><td align="left">MC</td><td char="." align="char">6</td><td align="left"/><td align="left">Low</td></tr>
###xml 730 732 723 725 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C7</td>
###xml 732 733 725 726 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">F</td>
###xml 733 735 726 728 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">73</td>
###xml 735 738 728 731 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">ABD</td>
###xml 738 740 731 733 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">MC</td>
###xml 740 742 733 735 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">24</td>
###xml 742 742 735 735 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 742 745 735 738 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Low</td>
###xml 730 745 723 738 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">C7</td><td align="left">F</td><td char="." align="char">73</td><td align="left">ABD</td><td align="left">MC</td><td char="." align="char">24</td><td align="left"/><td align="left">Low</td></tr>
###xml 745 747 738 740 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C8</td>
###xml 747 748 740 741 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">M</td>
###xml 748 750 741 743 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">63</td>
###xml 750 752 743 745 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">SS</td>
###xml 752 754 745 747 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">MC</td>
###xml 754 756 747 749 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">38</td>
###xml 756 756 749 749 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 756 759 749 752 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Low</td>
###xml 745 759 738 752 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">C8</td><td align="left">M</td><td char="." align="char">63</td><td align="left">SS</td><td align="left">MC</td><td char="." align="char">38</td><td align="left"/><td align="left">Low</td></tr>
###xml 659 759 652 752 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">AD7</td><td align="left">F</td><td char="." align="char">69</td><td align="left">AD</td><td align="left">MC</td><td char="." align="char">22</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD8</td><td align="left">F</td><td char="." align="char">79</td><td align="left">AD</td><td align="left">MC</td><td char="." align="char">18</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD9</td><td align="left">F</td><td char="." align="char">76</td><td align="left">AD</td><td align="left">MC</td><td char="." align="char">23</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">C6</td><td align="left">F</td><td char="." align="char">86</td><td align="left">HVD</td><td align="left">MC</td><td char="." align="char">6</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C7</td><td align="left">F</td><td char="." align="char">73</td><td align="left">ABD</td><td align="left">MC</td><td char="." align="char">24</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C8</td><td align="left">M</td><td char="." align="char">63</td><td align="left">SS</td><td align="left">MC</td><td char="." align="char">38</td><td align="left"/><td align="left">Low</td></tr></tbody>
###xml 591 759 584 752 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Case number</th><th align="left">Sex</th><th align="left">Age (years)</th><th align="left">Diagnosis</th><th align="left">Region</th><th align="left">PMI (h)</th><th align="left">Braak stage</th><th align="left">NIA Reagan</th></tr></thead><tbody><tr><td align="left">AD7</td><td align="left">F</td><td char="." align="char">69</td><td align="left">AD</td><td align="left">MC</td><td char="." align="char">22</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD8</td><td align="left">F</td><td char="." align="char">79</td><td align="left">AD</td><td align="left">MC</td><td char="." align="char">18</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD9</td><td align="left">F</td><td char="." align="char">76</td><td align="left">AD</td><td align="left">MC</td><td char="." align="char">23</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">C6</td><td align="left">F</td><td char="." align="char">86</td><td align="left">HVD</td><td align="left">MC</td><td char="." align="char">6</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C7</td><td align="left">F</td><td char="." align="char">73</td><td align="left">ABD</td><td align="left">MC</td><td char="." align="char">24</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C8</td><td align="left">M</td><td char="." align="char">63</td><td align="left">SS</td><td align="left">MC</td><td char="." align="char">38</td><td align="left"/><td align="left">Low</td></tr></tbody></table>
###xml 759 762 752 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PMI</italic>
###xml 781 783 774 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AD</italic>
###xml 805 806 798 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 815 816 808 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M</italic>
###xml 823 825 816 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MC</italic>
###xml 845 846 838 839 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 856 859 849 852 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HVD</italic>
###xml 891 894 884 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABD</italic>
###xml 916 918 909 911 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SS</italic>
###xml 759 931 752 924 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="22"><italic>PMI</italic> postmortem index, <italic>AD</italic> Alzheimer&#8217;s disease, <italic>F</italic> female, <italic>M</italic> male, <italic>MC</italic> midfrontal cortex, <italic>C</italic> control, <italic>HVD</italic> hypertensive vascular disease, <italic>ABD</italic> anoxic brain damage, <italic>SS</italic> septic shock</p>
###xml 759 931 752 924 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="22"><italic>PMI</italic> postmortem index, <italic>AD</italic> Alzheimer&#8217;s disease, <italic>F</italic> female, <italic>M</italic> male, <italic>MC</italic> midfrontal cortex, <italic>C</italic> control, <italic>HVD</italic> hypertensive vascular disease, <italic>ABD</italic> anoxic brain damage, <italic>SS</italic> septic shock</p></table-wrap-foot>
###xml 536 931 529 924 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="21">List of cases used for 2D PAGE and Western blots</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Case number</th><th align="left">Sex</th><th align="left">Age (years)</th><th align="left">Diagnosis</th><th align="left">Region</th><th align="left">PMI (h)</th><th align="left">Braak stage</th><th align="left">NIA Reagan</th></tr></thead><tbody><tr><td align="left">AD7</td><td align="left">F</td><td char="." align="char">69</td><td align="left">AD</td><td align="left">MC</td><td char="." align="char">22</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD8</td><td align="left">F</td><td char="." align="char">79</td><td align="left">AD</td><td align="left">MC</td><td char="." align="char">18</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">AD9</td><td align="left">F</td><td char="." align="char">76</td><td align="left">AD</td><td align="left">MC</td><td char="." align="char">23</td><td align="left">5/6</td><td align="left">High</td></tr><tr><td align="left">C6</td><td align="left">F</td><td char="." align="char">86</td><td align="left">HVD</td><td align="left">MC</td><td char="." align="char">6</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C7</td><td align="left">F</td><td char="." align="char">73</td><td align="left">ABD</td><td align="left">MC</td><td char="." align="char">24</td><td align="left"/><td align="left">Low</td></tr><tr><td align="left">C8</td><td align="left">M</td><td char="." align="char">63</td><td align="left">SS</td><td align="left">MC</td><td char="." align="char">38</td><td align="left"/><td align="left">Low</td></tr></tbody></table><table-wrap-foot><p textid="22"><italic>PMI</italic> postmortem index, <italic>AD</italic> Alzheimer&#8217;s disease, <italic>F</italic> female, <italic>M</italic> male, <italic>MC</italic> midfrontal cortex, <italic>C</italic> control, <italic>HVD</italic> hypertensive vascular disease, <italic>ABD</italic> anoxic brain damage, <italic>SS</italic> septic shock</p></table-wrap-foot></table-wrap>
Frozen tissue from midfrontal cortex of three AD brains and three control cases were homogenized in 50 mM Tris, 5 mM EDTA, 0.1% sodium azide, 1 mul/ml pepstatin and leupeptin and 0.3 mM of phenylmethylsulfonyl fluoride. Five milliliters of homogenization buffer was used per gram of brain tissue and homogenized using six passes of a motorized Wheaton Teflon pestle tissue grinder. Homogenates were centrifuged (500xg) for 10 min to remove particulate matter and snap-frozen at -80degreesC. Table 2 provides the details of these cases. Table 2List of cases used for 2D PAGE and Western blotsCase numberSexAge (years)DiagnosisRegionPMI (h)Braak stageNIA ReaganAD7F69ADMC225/6HighAD8F79ADMC185/6HighAD9F76ADMC235/6HighC6F86HVDMC6LowC7F73ABDMC24LowC8M63SSMC38LowPMI postmortem index, AD Alzheimer's disease, F female, M male, MC midfrontal cortex, C control, HVD hypertensive vascular disease, ABD anoxic brain damage, SS septic shock
###end p 20
###begin p 21
List of cases used for 2D PAGE and Western blots
###end p 21
###begin p 22
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PMI</italic>
###xml 22 24 22 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AD</italic>
###xml 46 47 46 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 56 57 56 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M</italic>
###xml 64 66 64 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MC</italic>
###xml 86 87 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 97 100 97 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HVD</italic>
###xml 132 135 132 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ABD</italic>
###xml 157 159 157 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SS</italic>
PMI postmortem index, AD Alzheimer's disease, F female, M male, MC midfrontal cortex, C control, HVD hypertensive vascular disease, ABD anoxic brain damage, SS septic shock
###end p 22
###begin title 23
Sample preparation
###end title 23
###begin p 24
###xml 463 464 461 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
Aliquots (100 mul) of Alzheimer's and control brain homogenates underwent a 2D clean up as per the Amersham Biosciences protocol. The samples were then resolubilized in 300 mul of TUC pH 4-7 buffer containing 7 M urea, 2 M thiourea, 4% CHAPS, 0.5% dithiothreitol, 0.5% IPG buffer pH 4-7. Samples were then assayed for total protein content. Prior to rehydration of the immobilized pH gradient strips, trace amounts of bromophenol blue was added to samples. Table 2 provides a list of cases used in the 2D electrophoresis.
###end p 24
###begin title 25
2D polyacrylamide gel electrophoresis (PAGE)
###end title 25
###begin title 26
Isoelectric focusing
###end title 26
###begin p 27
Isoelectric focusing was performed on 13 cm immobilized pH gradient strips (pH 4-7NL, Amersham Pharmacia) using an IPGphor (Amersham Pharmacia) isoelectric focusing unit. Samples were applied in gel rehydration (50 V, overnight) using 7 M urea, 2 M thiourea, 4% CHAPS, 0.5% dithiothreitol, 0.5% pharmalyte pH 4-7 with a trace of bromophenol blue as the re-swell buffer with a total loading volume of 280 mul including sample. Stained gels received a 400 mug protein load and Western blotting gels received a 200 mug load. IEF was performed for approximately60 kV h (500 V 30 min, 1,000 V 30 min, 1,000-8,000 V 30 min, 8,000 V 5-7 h, 1,000 V hold to end).
###end p 27
###begin title 28
SDS PAGE
###end title 28
###begin p 29
SDS PAGE was performed using 12.5% acrylamide gels. Immobilized pH gradient strips were incubated in SDS equilibration buffer containing 1% w/v dithiothreitol for 15 min followed by SDS equilibration buffer containing 4% w/v iodoacetamide for 15 min. Strips were then placed above the second dimension gels and overlaid with 1% low melting point agarose in Tris glycine gel running buffer. Electrophoresis was performed at 350 V for 2.5-3 h at 10degreesC. Protein gels were visualized using SYPRO ruby fluorescent stain (incubated for 2 h) and scanned using a Typhoon 9400 Variable Mode Imager (Amersham Biosciences).
###end p 29
###begin title 30
Western blotting
###end title 30
###begin p 31
###xml 112 113 112 113 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 189 195 <span type="species:ncbi:9986">rabbit</span>
###xml 272 276 <span type="species:ncbi:9925">goat</span>
Separated proteins were transferred onto low fluorescence PVDF membrane by semi-dry electroblotting at 0.8 mA/cm2 for 2 h. After blocking, the membranes were incubated in affinity-purified rabbit antiperoxiredoxin 6 antibodies (1/2,000) overnight at 4degreesC followed by goat antirabbit alkaline phosphatase antibodies (1/10,000) (Sigma) for 1 h and visualized using ECF substrate and a Typhoon 9400 Variable Mode Imager.
###end p 31
###begin title 32
Immunohistochemistry
###end title 32
###begin title 33
Localization of peroxiredoxin 6
###end title 33
###begin p 34
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
Immunohistochemical staining of AD and control tissue was carried out as previously described [30]. The cellular distribution of peroxiredoxin 6 was compared with the staining obtained with antibodies to specific cellular markers. Antibodies to GFAP (astrocytes), HLA (MHC2) (microglia), MBP (oligodendrocytes) and HuC/HuD (neurons) were used to map the distribution of peroxiredoxin 6.
###end p 34
###begin title 35
Colocalization of peroxiredoxin 6, Abeta and Tau
###end title 35
###begin p 36
###xml 372 374 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 35 41 <span type="species:ncbi:9986">rabbit</span>
###xml 63 68 <span type="species:ncbi:10090">mouse</span>
###xml 92 96 <span type="species:ncbi:9925">goat</span>
Brain sections were incubated with rabbit antiperoxiredoxin 6, mouse anti Abeta peptide and goat anti tau antibodies overnight and detected with secondary antibodies conjugated to fluorescent fluorophores Cy5, Alexa 488 and Cy3, respectively. Sections were examined using a Bio-Rad Confocal laser scanning microscope and Bio-Rad software package, as previously described [30].
###end p 36
###begin title 37
Cell counting
###end title 37
###begin p 38
###xml 167 168 167 168 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 574 575 574 575 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 673 674 673 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 738 745 738 745 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 745 788 745 788 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="39">Interactions examined in cell counting data</p>
###xml 745 788 745 788 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="39">Interactions examined in cell counting data</p></caption>
###xml 788 809 788 809 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Interactions examined</th>
###xml 809 810 809 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 809 816 809 816 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>F</italic> value</th>
###xml 825 826 825 826 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
###xml 828 829 828 829 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 816 837 816 837 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Critical <italic>F</italic> (<italic>P</italic>&#160;=&#160;0.01)</th>
###xml 837 857 837 857 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Significance (&gt;0.01)</th>
###xml 788 857 788 857 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Interactions examined</th><th align="left"><italic>F</italic> value</th><th align="left">Critical <italic>F</italic> (<italic>P</italic>&#160;=&#160;0.01)</th><th align="left">Significance (&gt;0.01)</th></tr>
###xml 788 857 788 857 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Interactions examined</th><th align="left"><italic>F</italic> value</th><th align="left">Critical <italic>F</italic> (<italic>P</italic>&#160;=&#160;0.01)</th><th align="left">Significance (&gt;0.01)</th></tr></thead>
###xml 857 923 857 923 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Are there differences in AD (C, A, H, MC) gray matter cell counts?</td>
###xml 923 927 923 927 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.00</td>
###xml 927 931 927 931 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.94</td>
###xml 931 933 931 933 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NS</td>
###xml 857 933 857 933 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Are there differences in AD (C, A, H, MC) gray matter cell counts?</td><td char="." align="char">1.00</td><td char="." align="char">4.94</td><td align="left">NS</td></tr>
###xml 933 1000 933 1000 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Are there differences in AD (C, A, H, MC) white matter cell counts?</td>
###xml 1000 1004 1000 1004 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.23</td>
###xml 1004 1008 1004 1008 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.94</td>
###xml 1008 1010 1008 1010 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NS</td>
###xml 933 1010 933 1010 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Are there differences in AD (C, A, H, MC) white matter cell counts?</td><td char="." align="char">1.23</td><td char="." align="char">4.94</td><td align="left">NS</td></tr>
###xml 1010 1081 1010 1081 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Are there differences in control (C, A, H, MC) gray matter cell counts?</td>
###xml 1081 1085 1081 1085 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.62</td>
###xml 1085 1089 1085 1089 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.94</td>
###xml 1089 1091 1089 1091 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NS</td>
###xml 1010 1091 1010 1091 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Are there differences in control (C, A, H, MC) gray matter cell counts?</td><td char="." align="char">0.62</td><td char="." align="char">4.94</td><td align="left">NS</td></tr>
###xml 1091 1163 1091 1163 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Are there differences in control (C, A, H, MC) white matter cell counts?</td>
###xml 1163 1167 1163 1167 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.25</td>
###xml 1167 1171 1167 1171 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">4.94</td>
###xml 1171 1173 1171 1173 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">NS</td>
###xml 1091 1173 1091 1173 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Are there differences in control (C, A, H, MC) white matter cell counts?</td><td char="." align="char">0.25</td><td char="." align="char">4.94</td><td align="left">NS</td></tr>
###xml 1173 1250 1173 1250 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Are there differences between gray and white matter cell counts in AD tissue?</td>
###xml 1250 1254 1250 1254 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">89.3</td>
###xml 1254 1258 1254 1258 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7.21</td>
###xml 1258 1259 1258 1259 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">S</td>
###xml 1173 1259 1173 1259 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Are there differences between gray and white matter cell counts in AD tissue?</td><td char="." align="char">89.3</td><td char="." align="char">7.21</td><td align="left">S</td></tr>
###xml 1259 1341 1259 1341 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Are there differences between gray and white matter cell counts in control tissue?</td>
###xml 1341 1345 1341 1345 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">14.5</td>
###xml 1345 1349 1345 1349 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7.21</td>
###xml 1349 1350 1349 1350 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">S</td>
###xml 1259 1350 1259 1350 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Are there differences between gray and white matter cell counts in control tissue?</td><td char="." align="char">14.5</td><td char="." align="char">7.21</td><td align="left">S</td></tr>
###xml 1350 1429 1350 1429 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Are there differences in gray matter cell counts between control and AD tissue?</td>
###xml 1429 1432 1429 1432 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">299</td>
###xml 1432 1436 1432 1436 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7.21</td>
###xml 1436 1437 1436 1437 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">S</td>
###xml 1350 1437 1350 1437 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Are there differences in gray matter cell counts between control and AD tissue?</td><td char="." align="char">299</td><td char="." align="char">7.21</td><td align="left">S</td></tr>
###xml 1437 1517 1437 1517 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Are there differences in white matter cell counts between control and AD tissue?</td>
###xml 1517 1521 1517 1521 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">28.0</td>
###xml 1521 1525 1521 1525 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">7.21</td>
###xml 1525 1526 1525 1526 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">S</td>
###xml 1437 1526 1437 1526 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Are there differences in white matter cell counts between control and AD tissue?</td><td char="." align="char">28.0</td><td char="." align="char">7.21</td><td align="left">S</td></tr>
###xml 857 1526 857 1526 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Are there differences in AD (C, A, H, MC) gray matter cell counts?</td><td char="." align="char">1.00</td><td char="." align="char">4.94</td><td align="left">NS</td></tr><tr><td align="left">Are there differences in AD (C, A, H, MC) white matter cell counts?</td><td char="." align="char">1.23</td><td char="." align="char">4.94</td><td align="left">NS</td></tr><tr><td align="left">Are there differences in control (C, A, H, MC) gray matter cell counts?</td><td char="." align="char">0.62</td><td char="." align="char">4.94</td><td align="left">NS</td></tr><tr><td align="left">Are there differences in control (C, A, H, MC) white matter cell counts?</td><td char="." align="char">0.25</td><td char="." align="char">4.94</td><td align="left">NS</td></tr><tr><td align="left">Are there differences between gray and white matter cell counts in AD tissue?</td><td char="." align="char">89.3</td><td char="." align="char">7.21</td><td align="left">S</td></tr><tr><td align="left">Are there differences between gray and white matter cell counts in control tissue?</td><td char="." align="char">14.5</td><td char="." align="char">7.21</td><td align="left">S</td></tr><tr><td align="left">Are there differences in gray matter cell counts between control and AD tissue?</td><td char="." align="char">299</td><td char="." align="char">7.21</td><td align="left">S</td></tr><tr><td align="left">Are there differences in white matter cell counts between control and AD tissue?</td><td char="." align="char">28.0</td><td char="." align="char">7.21</td><td align="left">S</td></tr></tbody>
###xml 788 1526 788 1526 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Interactions examined</th><th align="left"><italic>F</italic> value</th><th align="left">Critical <italic>F</italic> (<italic>P</italic>&#160;=&#160;0.01)</th><th align="left">Significance (&gt;0.01)</th></tr></thead><tbody><tr><td align="left">Are there differences in AD (C, A, H, MC) gray matter cell counts?</td><td char="." align="char">1.00</td><td char="." align="char">4.94</td><td align="left">NS</td></tr><tr><td align="left">Are there differences in AD (C, A, H, MC) white matter cell counts?</td><td char="." align="char">1.23</td><td char="." align="char">4.94</td><td align="left">NS</td></tr><tr><td align="left">Are there differences in control (C, A, H, MC) gray matter cell counts?</td><td char="." align="char">0.62</td><td char="." align="char">4.94</td><td align="left">NS</td></tr><tr><td align="left">Are there differences in control (C, A, H, MC) white matter cell counts?</td><td char="." align="char">0.25</td><td char="." align="char">4.94</td><td align="left">NS</td></tr><tr><td align="left">Are there differences between gray and white matter cell counts in AD tissue?</td><td char="." align="char">89.3</td><td char="." align="char">7.21</td><td align="left">S</td></tr><tr><td align="left">Are there differences between gray and white matter cell counts in control tissue?</td><td char="." align="char">14.5</td><td char="." align="char">7.21</td><td align="left">S</td></tr><tr><td align="left">Are there differences in gray matter cell counts between control and AD tissue?</td><td char="." align="char">299</td><td char="." align="char">7.21</td><td align="left">S</td></tr><tr><td align="left">Are there differences in white matter cell counts between control and AD tissue?</td><td char="." align="char">28.0</td><td char="." align="char">7.21</td><td align="left">S</td></tr></tbody></table>
###xml 1526 1528 1526 1528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AD</italic>
###xml 1550 1552 1550 1552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NS</italic>
###xml 1570 1571 1570 1571 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 1585 1586 1585 1586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 1598 1599 1598 1599 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 1610 1611 1610 1611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 1625 1627 1625 1627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MC</italic>
###xml 1526 1645 1526 1645 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40"><italic>AD</italic> Alzheimer&#8217;s disease, <italic>NS</italic> not significant, <italic>S</italic> significant, <italic>C</italic> cingulate, <italic>A</italic> amygdala, <italic>H</italic> hippocampus, <italic>MC</italic> midfrontal cortex</p>
###xml 1526 1645 1526 1645 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="40"><italic>AD</italic> Alzheimer&#8217;s disease, <italic>NS</italic> not significant, <italic>S</italic> significant, <italic>C</italic> cingulate, <italic>A</italic> amygdala, <italic>H</italic> hippocampus, <italic>MC</italic> midfrontal cortex</p></table-wrap-foot>
###xml 738 1645 738 1645 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="39">Interactions examined in cell counting data</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Interactions examined</th><th align="left"><italic>F</italic> value</th><th align="left">Critical <italic>F</italic> (<italic>P</italic>&#160;=&#160;0.01)</th><th align="left">Significance (&gt;0.01)</th></tr></thead><tbody><tr><td align="left">Are there differences in AD (C, A, H, MC) gray matter cell counts?</td><td char="." align="char">1.00</td><td char="." align="char">4.94</td><td align="left">NS</td></tr><tr><td align="left">Are there differences in AD (C, A, H, MC) white matter cell counts?</td><td char="." align="char">1.23</td><td char="." align="char">4.94</td><td align="left">NS</td></tr><tr><td align="left">Are there differences in control (C, A, H, MC) gray matter cell counts?</td><td char="." align="char">0.62</td><td char="." align="char">4.94</td><td align="left">NS</td></tr><tr><td align="left">Are there differences in control (C, A, H, MC) white matter cell counts?</td><td char="." align="char">0.25</td><td char="." align="char">4.94</td><td align="left">NS</td></tr><tr><td align="left">Are there differences between gray and white matter cell counts in AD tissue?</td><td char="." align="char">89.3</td><td char="." align="char">7.21</td><td align="left">S</td></tr><tr><td align="left">Are there differences between gray and white matter cell counts in control tissue?</td><td char="." align="char">14.5</td><td char="." align="char">7.21</td><td align="left">S</td></tr><tr><td align="left">Are there differences in gray matter cell counts between control and AD tissue?</td><td char="." align="char">299</td><td char="." align="char">7.21</td><td align="left">S</td></tr><tr><td align="left">Are there differences in white matter cell counts between control and AD tissue?</td><td char="." align="char">28.0</td><td char="." align="char">7.21</td><td align="left">S</td></tr></tbody></table><table-wrap-foot><p textid="40"><italic>AD</italic> Alzheimer&#8217;s disease, <italic>NS</italic> not significant, <italic>S</italic> significant, <italic>C</italic> cingulate, <italic>A</italic> amygdala, <italic>H</italic> hippocampus, <italic>MC</italic> midfrontal cortex</p></table-wrap-foot></table-wrap>
Cell counting was carried out blind on masked sections, and peroxiredoxin 6 positive astrocytes were counted at 20x magnification with a graticule eye piece (0.0625 mm2) using an Olympus HO-2 microscope on brain tissue from six AD and six control cases. In each case, five regions were randomly selected to give a uniform representation of the white and gray matter in the cingulate, hippocampus, amygdala and midfrontal cortex. The number of positive cells from each of the five areas was averaged and divided by the area of the graticule eyepiece and expressed as cells/mm2. The data was then analyzed using a one-way ANOVA that examined the interactions listed in Table 3. The significance was determined at 0.01 level of probability. Table 3Interactions examined in cell counting dataInteractions examinedF valueCritical F (P = 0.01)Significance (>0.01)Are there differences in AD (C, A, H, MC) gray matter cell counts?1.004.94NSAre there differences in AD (C, A, H, MC) white matter cell counts?1.234.94NSAre there differences in control (C, A, H, MC) gray matter cell counts?0.624.94NSAre there differences in control (C, A, H, MC) white matter cell counts?0.254.94NSAre there differences between gray and white matter cell counts in AD tissue?89.37.21SAre there differences between gray and white matter cell counts in control tissue?14.57.21SAre there differences in gray matter cell counts between control and AD tissue?2997.21SAre there differences in white matter cell counts between control and AD tissue?28.07.21SAD Alzheimer's disease, NS not significant, S significant, C cingulate, A amygdala, H hippocampus, MC midfrontal cortex
###end p 38
###begin p 39
Interactions examined in cell counting data
###end p 39
###begin p 40
###xml 0 2 0 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AD</italic>
###xml 24 26 24 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NS</italic>
###xml 44 45 44 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S</italic>
###xml 59 60 59 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C</italic>
###xml 72 73 72 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A</italic>
###xml 84 85 84 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H</italic>
###xml 99 101 99 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MC</italic>
AD Alzheimer's disease, NS not significant, S significant, C cingulate, A amygdala, H hippocampus, MC midfrontal cortex
###end p 40
###begin title 41
Results
###end title 41
###begin title 42
###xml 38 43 <span type="species:ncbi:9606">human</span>
Molecular forms of peroxiredoxin 6 in human brain
###end title 42
###begin p 43
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 342 343 342 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 492 493 492 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 496 502 496 502 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 502 503 502 503 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 505 506 505 506 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 628 629 628 629 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 631 632 631 632 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 645 651 645 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pI 4&#8211;6</italic>
###xml 771 772 771 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Y</italic>
###xml 840 843 840 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">box</italic>
###xml 915 920 915 920 <italic xmlns:xlink="http://www.w3.org/1999/xlink">spots</italic>
###xml 502 988 502 988 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="44"><bold>a</bold>, <bold>b</bold> A two-dimensional PAGE gel and blot of AD brain tissue (Case AD7) and a corresponding control brain gel and blot panels (<bold>c</bold>, <bold>d</bold>) (Case C7). <italic>pI 4&#8211;6</italic> is indicated between the gel and blots and the molecular weight of the standards (Std) in kilo Daltons is shown on the <italic>Y</italic>-axis. The gels were stained with SYPRO ruby fluorescent stain. The <italic>box</italic> indicates the location of the molecular forms of peroxiredoxin 6. Some <italic>spots</italic> are shown on the blots to indicate the range of peroxiredoxin 6 pIs</p>
###xml 502 988 502 988 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="44"><bold>a</bold>, <bold>b</bold> A two-dimensional PAGE gel and blot of AD brain tissue (Case AD7) and a corresponding control brain gel and blot panels (<bold>c</bold>, <bold>d</bold>) (Case C7). <italic>pI 4&#8211;6</italic> is indicated between the gel and blots and the molecular weight of the standards (Std) in kilo Daltons is shown on the <italic>Y</italic>-axis. The gels were stained with SYPRO ruby fluorescent stain. The <italic>box</italic> indicates the location of the molecular forms of peroxiredoxin 6. Some <italic>spots</italic> are shown on the blots to indicate the range of peroxiredoxin 6 pIs</p></caption>
###xml 988 988 988 988 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_373_Fig1_HTML" id="MO1"/>
###xml 496 988 496 988 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="44"><bold>a</bold>, <bold>b</bold> A two-dimensional PAGE gel and blot of AD brain tissue (Case AD7) and a corresponding control brain gel and blot panels (<bold>c</bold>, <bold>d</bold>) (Case C7). <italic>pI 4&#8211;6</italic> is indicated between the gel and blots and the molecular weight of the standards (Std) in kilo Daltons is shown on the <italic>Y</italic>-axis. The gels were stained with SYPRO ruby fluorescent stain. The <italic>box</italic> indicates the location of the molecular forms of peroxiredoxin 6. Some <italic>spots</italic> are shown on the blots to indicate the range of peroxiredoxin 6 pIs</p></caption><graphic position="anchor" xlink:href="401_2008_373_Fig1_HTML" id="MO1"/></fig>
###xml 988 994 988 994 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1103 1104 1103 1104 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1158 1159 1158 1159 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1205 1208 1205 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;8</italic>
###xml 994 1423 994 1423 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="45">A composite figure at higher magnification showing the range of molecular forms in three cases of AD tissue (<bold>a</bold> AD7, AD8 and AD9) and three cases of control tissue (<bold>b</bold> C7, C6 and C8). The range of molecular forms <italic>1&#8211;8</italic> is shown, but not all forms are present in all cases. Although there are slight variations between blots, the respective pIs are as follows: 1 (5.3), 2 (5.4), 3 (5.6), 4 (5.75), 5 (5.85), 6 (5.9), 7 (5.95), 8 (6.1)</p>
###xml 994 1423 994 1423 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="45">A composite figure at higher magnification showing the range of molecular forms in three cases of AD tissue (<bold>a</bold> AD7, AD8 and AD9) and three cases of control tissue (<bold>b</bold> C7, C6 and C8). The range of molecular forms <italic>1&#8211;8</italic> is shown, but not all forms are present in all cases. Although there are slight variations between blots, the respective pIs are as follows: 1 (5.3), 2 (5.4), 3 (5.6), 4 (5.75), 5 (5.85), 6 (5.9), 7 (5.95), 8 (6.1)</p></caption>
###xml 1423 1423 1423 1423 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_373_Fig2_HTML" id="MO2"/>
###xml 988 1423 988 1423 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="45">A composite figure at higher magnification showing the range of molecular forms in three cases of AD tissue (<bold>a</bold> AD7, AD8 and AD9) and three cases of control tissue (<bold>b</bold> C7, C6 and C8). The range of molecular forms <italic>1&#8211;8</italic> is shown, but not all forms are present in all cases. Although there are slight variations between blots, the respective pIs are as follows: 1 (5.3), 2 (5.4), 3 (5.6), 4 (5.75), 5 (5.85), 6 (5.9), 7 (5.95), 8 (6.1)</p></caption><graphic position="anchor" xlink:href="401_2008_373_Fig2_HTML" id="MO2"/></fig>
###xml 80 83 <span type="species:ncbi:10116">rat</span>
###xml 93 98 <span type="species:ncbi:9606">human</span>
We have previously shown that this antibody is specific for a 26 kDa monomer in rat lung and human brain, and the N-terminal sequence is identical to peroxiredoxin 6 [30, 31]. Two-dimensional PAGE and Western blotting of AD and control brain homogenates indicated that this protein exists as three major and five minor forms as shown in Fig. 1a-d. Although the loadings were consistent, the five minor forms could not be detected on all gels. For comparison, the spots were labeled 1-8 (Fig. 2). Fig. 1a, b A two-dimensional PAGE gel and blot of AD brain tissue (Case AD7) and a corresponding control brain gel and blot panels (c, d) (Case C7). pI 4-6 is indicated between the gel and blots and the molecular weight of the standards (Std) in kilo Daltons is shown on the Y-axis. The gels were stained with SYPRO ruby fluorescent stain. The box indicates the location of the molecular forms of peroxiredoxin 6. Some spots are shown on the blots to indicate the range of peroxiredoxin 6 pIsFig. 2A composite figure at higher magnification showing the range of molecular forms in three cases of AD tissue (a AD7, AD8 and AD9) and three cases of control tissue (b C7, C6 and C8). The range of molecular forms 1-8 is shown, but not all forms are present in all cases. Although there are slight variations between blots, the respective pIs are as follows: 1 (5.3), 2 (5.4), 3 (5.6), 4 (5.75), 5 (5.85), 6 (5.9), 7 (5.95), 8 (6.1)
###end p 43
###begin p 44
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 3 4 3 4 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 126 127 126 127 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 129 130 129 130 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 143 149 143 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">pI 4&#8211;6</italic>
###xml 269 270 269 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Y</italic>
###xml 338 341 338 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink">box</italic>
###xml 413 418 413 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">spots</italic>
a, b A two-dimensional PAGE gel and blot of AD brain tissue (Case AD7) and a corresponding control brain gel and blot panels (c, d) (Case C7). pI 4-6 is indicated between the gel and blots and the molecular weight of the standards (Std) in kilo Daltons is shown on the Y-axis. The gels were stained with SYPRO ruby fluorescent stain. The box indicates the location of the molecular forms of peroxiredoxin 6. Some spots are shown on the blots to indicate the range of peroxiredoxin 6 pIs
###end p 44
###begin p 45
###xml 109 110 109 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 164 165 164 165 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 211 214 211 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">1&#8211;8</italic>
A composite figure at higher magnification showing the range of molecular forms in three cases of AD tissue (a AD7, AD8 and AD9) and three cases of control tissue (b C7, C6 and C8). The range of molecular forms 1-8 is shown, but not all forms are present in all cases. Although there are slight variations between blots, the respective pIs are as follows: 1 (5.3), 2 (5.4), 3 (5.6), 4 (5.75), 5 (5.85), 6 (5.9), 7 (5.95), 8 (6.1)
###end p 45
###begin p 46
###xml 457 458 457 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 625 626 625 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
The respective pIs of the eight forms are 5.3, 5.4, 5.6, 5.75, 5.85, 5.9, 5.95 and 6.1. The three major forms were 3, 6 and 7 and the average pIs of these were 5.59, 5.88 and 5.96 for AD tissue and 5.59, 5.80 and 5.86 for control tissue. These major forms were consistent in all homogenates. The intensity of the three major forms was analyzed using the Typhoon imager and the intensity of spots 6 and 7 was reversed in the AD and control homogenates (Fig. 2). Minor forms 1 and 2 were present in AD homogenates but absent in the control tissue, while minor form 8 was present in control tissue but absent in AD tissue (Fig. 2).
###end p 46
###begin title 47
Cellular distribution of peroxiredoxin 6 in control and AD brain tissue
###end title 47
###begin p 48
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 214 215 214 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig3" ref-type="fig">3</xref>
###xml 329 335 329 335 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;3</label>
###xml 411 412 411 412 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 421 426 421 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 428 429 428 429 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 440 443 440 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 445 446 445 446 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 461 464 461 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar</italic>
###xml 499 500 498 499 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 509 514 508 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 516 517 515 516 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 528 531 527 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 533 534 532 533 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 549 552 548 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar</italic>
###xml 592 593 590 591 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 602 607 600 605 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 609 610 607 608 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 620 623 618 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 625 626 623 624 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 641 644 639 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar</italic>
###xml 676 677 673 674 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 686 691 683 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 693 694 690 691 <bold xmlns:xlink="http://www.w3.org/1999/xlink">k</bold>
###xml 703 706 700 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 708 709 705 706 <bold xmlns:xlink="http://www.w3.org/1999/xlink">l</bold>
###xml 724 727 721 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar</italic>
###xml 335 784 335 780 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="49">Confocal localization of peroxiredoxin 6 (P6) with GFAP (astrocyte marker) (<bold>a</bold> P6, Cy2-<italic>green</italic>; <bold>b</bold> GFAP, Cy3-<italic>red</italic>; <bold>c</bold> merged image; <italic>bar</italic>&#160;25&#160;&#956;M), MHC2 (microglia marker) (<bold>d</bold> P6, Cy2-<italic>green</italic>; <bold>e</bold> MHC2, Cy3-<italic>red</italic>; <bold>f</bold> merged image; <italic>bar</italic>&#160;25&#160;&#956;M), MBP (oligodendrocyte marker) (<bold>g</bold> P6, Cy2-<italic>green</italic>; <bold>h</bold> MBP, Cy3-<italic>red</italic>; <bold>i</bold> merged image; <italic>bar</italic>&#160;10&#160;&#956;M), Hu (neuronal marker) (<bold>j</bold> P6, Cy2-<italic>green</italic>; <bold>k</bold> Hu, Cy3-<italic>red</italic>; <bold>l</bold> merged image; <italic>bar</italic>&#160;25&#160;&#956;M). Cell localization was performed using AD tissue</p>
###xml 335 784 335 780 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="49">Confocal localization of peroxiredoxin 6 (P6) with GFAP (astrocyte marker) (<bold>a</bold> P6, Cy2-<italic>green</italic>; <bold>b</bold> GFAP, Cy3-<italic>red</italic>; <bold>c</bold> merged image; <italic>bar</italic>&#160;25&#160;&#956;M), MHC2 (microglia marker) (<bold>d</bold> P6, Cy2-<italic>green</italic>; <bold>e</bold> MHC2, Cy3-<italic>red</italic>; <bold>f</bold> merged image; <italic>bar</italic>&#160;25&#160;&#956;M), MBP (oligodendrocyte marker) (<bold>g</bold> P6, Cy2-<italic>green</italic>; <bold>h</bold> MBP, Cy3-<italic>red</italic>; <bold>i</bold> merged image; <italic>bar</italic>&#160;10&#160;&#956;M), Hu (neuronal marker) (<bold>j</bold> P6, Cy2-<italic>green</italic>; <bold>k</bold> Hu, Cy3-<italic>red</italic>; <bold>l</bold> merged image; <italic>bar</italic>&#160;25&#160;&#956;M). Cell localization was performed using AD tissue</p></caption>
###xml 784 784 780 780 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_373_Fig3_HTML" id="MO3"/>
###xml 329 784 329 780 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig3"><label>Fig.&#160;3</label><caption><p textid="49">Confocal localization of peroxiredoxin 6 (P6) with GFAP (astrocyte marker) (<bold>a</bold> P6, Cy2-<italic>green</italic>; <bold>b</bold> GFAP, Cy3-<italic>red</italic>; <bold>c</bold> merged image; <italic>bar</italic>&#160;25&#160;&#956;M), MHC2 (microglia marker) (<bold>d</bold> P6, Cy2-<italic>green</italic>; <bold>e</bold> MHC2, Cy3-<italic>red</italic>; <bold>f</bold> merged image; <italic>bar</italic>&#160;25&#160;&#956;M), MBP (oligodendrocyte marker) (<bold>g</bold> P6, Cy2-<italic>green</italic>; <bold>h</bold> MBP, Cy3-<italic>red</italic>; <bold>i</bold> merged image; <italic>bar</italic>&#160;10&#160;&#956;M), Hu (neuronal marker) (<bold>j</bold> P6, Cy2-<italic>green</italic>; <bold>k</bold> Hu, Cy3-<italic>red</italic>; <bold>l</bold> merged image; <italic>bar</italic>&#160;25&#160;&#956;M). Cell localization was performed using AD tissue</p></caption><graphic position="anchor" xlink:href="401_2008_373_Fig3_HTML" id="MO3"/></fig>
###xml 47 52 <span type="species:ncbi:9606">human</span>
Using immunohistochemical markers for specific human brain cell types, we have shown that peroxiredoxin 6 is abundant in reactive astrocytes (Fig. 3a-c) in AD tissue and present in very low levels in neurons (Fig. 3j-l). We were not able to detect peroxiredoxin 6 in either microglia (Fig. 3d-f) or oligodendrocytes (Fig. 3g-i). Fig. 3Confocal localization of peroxiredoxin 6 (P6) with GFAP (astrocyte marker) (a P6, Cy2-green; b GFAP, Cy3-red; c merged image; bar 25 muM), MHC2 (microglia marker) (d P6, Cy2-green; e MHC2, Cy3-red; f merged image; bar 25 muM), MBP (oligodendrocyte marker) (g P6, Cy2-green; h MBP, Cy3-red; i merged image; bar 10 muM), Hu (neuronal marker) (j P6, Cy2-green; k Hu, Cy3-red; l merged image; bar 25 muM). Cell localization was performed using AD tissue
###end p 48
###begin p 49
###xml 76 77 76 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 86 91 86 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 93 94 93 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 105 108 105 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 110 111 110 111 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 126 129 126 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar</italic>
###xml 164 165 163 164 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 174 179 173 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 181 182 180 181 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 193 196 192 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 198 199 197 198 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 214 217 213 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar</italic>
###xml 257 258 255 256 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g</bold>
###xml 267 272 265 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 274 275 272 273 <bold xmlns:xlink="http://www.w3.org/1999/xlink">h</bold>
###xml 285 288 283 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 290 291 288 289 <bold xmlns:xlink="http://www.w3.org/1999/xlink">i</bold>
###xml 306 309 304 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar</italic>
###xml 341 342 338 339 <bold xmlns:xlink="http://www.w3.org/1999/xlink">j</bold>
###xml 351 356 348 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 358 359 355 356 <bold xmlns:xlink="http://www.w3.org/1999/xlink">k</bold>
###xml 368 371 365 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 373 374 370 371 <bold xmlns:xlink="http://www.w3.org/1999/xlink">l</bold>
###xml 389 392 386 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar</italic>
Confocal localization of peroxiredoxin 6 (P6) with GFAP (astrocyte marker) (a P6, Cy2-green; b GFAP, Cy3-red; c merged image; bar 25 muM), MHC2 (microglia marker) (d P6, Cy2-green; e MHC2, Cy3-red; f merged image; bar 25 muM), MBP (oligodendrocyte marker) (g P6, Cy2-green; h MBP, Cy3-red; i merged image; bar 10 muM), Hu (neuronal marker) (j P6, Cy2-green; k Hu, Cy3-red; l merged image; bar 25 muM). Cell localization was performed using AD tissue
###end p 49
###begin p 50
###xml 270 271 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig4" ref-type="fig">4</xref>
###xml 536 537 536 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig5" ref-type="fig">5</xref>
###xml 540 546 540 546 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;4</label>
###xml 615 616 615 616 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 641 642 641 642 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 546 643 546 643 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="51">Oil immersion image (&#215;1,000) of typical astrocyte seen in AD cortex (<bold>a</bold>) and in control cortex (<bold>b</bold>)</p>
###xml 546 643 546 643 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="51">Oil immersion image (&#215;1,000) of typical astrocyte seen in AD cortex (<bold>a</bold>) and in control cortex (<bold>b</bold>)</p></caption>
###xml 643 643 643 643 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_373_Fig4_HTML" id="MO4"/>
###xml 540 643 540 643 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig4"><label>Fig.&#160;4</label><caption><p textid="51">Oil immersion image (&#215;1,000) of typical astrocyte seen in AD cortex (<bold>a</bold>) and in control cortex (<bold>b</bold>)</p></caption><graphic position="anchor" xlink:href="401_2008_373_Fig4_HTML" id="MO4"/></fig>
###xml 643 649 643 649 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;5</label>
###xml 740 744 740 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gray</italic>
###xml 753 754 753 754 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 760 765 760 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink">white</italic>
###xml 774 775 774 775 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 793 797 793 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gray</italic>
###xml 806 807 806 807 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 828 833 828 833 <italic xmlns:xlink="http://www.w3.org/1999/xlink">white</italic>
###xml 842 843 842 843 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 649 878 649 878 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="52">Light immunohistochemistry (DAB substrate) of peroxiredoxin 6 staining of astrocytes in AD <italic>gray</italic> matter (<bold>a</bold>), AD <italic>white</italic> matter (<bold>b</bold>), control tissue <italic>gray</italic> matter (<bold>c</bold>) and control tissue <italic>white</italic> matter (<bold>d</bold>). All images at &#215;200 magnification</p>
###xml 649 878 649 878 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="52">Light immunohistochemistry (DAB substrate) of peroxiredoxin 6 staining of astrocytes in AD <italic>gray</italic> matter (<bold>a</bold>), AD <italic>white</italic> matter (<bold>b</bold>), control tissue <italic>gray</italic> matter (<bold>c</bold>) and control tissue <italic>white</italic> matter (<bold>d</bold>). All images at &#215;200 magnification</p></caption>
###xml 878 878 878 878 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_373_Fig5_HTML" id="MO5"/>
###xml 643 878 643 878 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig5"><label>Fig.&#160;5</label><caption><p textid="52">Light immunohistochemistry (DAB substrate) of peroxiredoxin 6 staining of astrocytes in AD <italic>gray</italic> matter (<bold>a</bold>), AD <italic>white</italic> matter (<bold>b</bold>), control tissue <italic>gray</italic> matter (<bold>c</bold>) and control tissue <italic>white</italic> matter (<bold>d</bold>). All images at &#215;200 magnification</p></caption><graphic position="anchor" xlink:href="401_2008_373_Fig5_HTML" id="MO5"/></fig>
There was a marked contrast between the staining of control and reactive astrocytes in AD. Reactive astrocytes in AD were hypertrophied with abundant staining of peroxiredoxin 6, while in control astrocytes the staining was confined to a "halo" around the nucleus (Fig. 4). The increased staining of peroxiredoxin 6 was seen in all regions examined and in both gray and white matter, but the staining was not evenly distributed and some regions on the same section were heavily labeled but adjacent regions showed little staining (Fig. 5). Fig. 4Oil immersion image (x1,000) of typical astrocyte seen in AD cortex (a) and in control cortex (b)Fig. 5Light immunohistochemistry (DAB substrate) of peroxiredoxin 6 staining of astrocytes in AD gray matter (a), AD white matter (b), control tissue gray matter (c) and control tissue white matter (d). All images at x200 magnification
###end p 50
###begin p 51
###xml 69 70 69 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 95 96 95 96 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
Oil immersion image (x1,000) of typical astrocyte seen in AD cortex (a) and in control cortex (b)
###end p 51
###begin p 52
###xml 91 95 91 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gray</italic>
###xml 104 105 104 105 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 111 116 111 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">white</italic>
###xml 125 126 125 126 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 144 148 144 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">gray</italic>
###xml 157 158 157 158 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 179 184 179 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">white</italic>
###xml 193 194 193 194 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
Light immunohistochemistry (DAB substrate) of peroxiredoxin 6 staining of astrocytes in AD gray matter (a), AD white matter (b), control tissue gray matter (c) and control tissue white matter (d). All images at x200 magnification
###end p 52
###begin title 53
Cell counting
###end title 53
###begin p 54
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 439 440 439 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig6" ref-type="fig">6</xref>
###xml 636 637 636 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 639 645 639 645 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;6</label>
###xml 647 656 647 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar chart</italic>
###xml 778 780 778 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WM</italic>
###xml 795 797 795 797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GM</italic>
###xml 811 815 811 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cing</italic>
###xml 827 830 827 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Amy</italic>
###xml 841 844 841 844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MFC</italic>
###xml 864 867 864 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hip</italic>
###xml 914 915 912 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 645 932 645 930 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="55">A <italic>bar chart</italic> showing the range of cell counts in different brain regions in gray and white matter in control tissue and in AD tissue. <italic>WM</italic> white matter, <italic>GM</italic> gray matter, <italic>Cing</italic> cingulate, <italic>Amy</italic> amygdala, <italic>MFC</italic> midfrontal cortex, <italic>Hip</italic> hippocampus. Counts are shown as mean&#160;&#177;&#160;SE, <italic>N</italic>&#160;=&#160;6 in all cases</p>
###xml 645 932 645 930 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="55">A <italic>bar chart</italic> showing the range of cell counts in different brain regions in gray and white matter in control tissue and in AD tissue. <italic>WM</italic> white matter, <italic>GM</italic> gray matter, <italic>Cing</italic> cingulate, <italic>Amy</italic> amygdala, <italic>MFC</italic> midfrontal cortex, <italic>Hip</italic> hippocampus. Counts are shown as mean&#160;&#177;&#160;SE, <italic>N</italic>&#160;=&#160;6 in all cases</p></caption>
###xml 932 932 930 930 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_373_Fig6_HTML" id="MO6"/>
###xml 639 932 639 930 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig6"><label>Fig.&#160;6</label><caption><p textid="55">A <italic>bar chart</italic> showing the range of cell counts in different brain regions in gray and white matter in control tissue and in AD tissue. <italic>WM</italic> white matter, <italic>GM</italic> gray matter, <italic>Cing</italic> cingulate, <italic>Amy</italic> amygdala, <italic>MFC</italic> midfrontal cortex, <italic>Hip</italic> hippocampus. Counts are shown as mean&#160;&#177;&#160;SE, <italic>N</italic>&#160;=&#160;6 in all cases</p></caption><graphic position="anchor" xlink:href="401_2008_373_Fig6_HTML" id="MO6"/></fig>
In AD and control tissue, peroxiredoxin 6 was colocalized with GFAP, indicating that the upregulation is occurring in astrocytes, which is similar to what was found in PD and dementia with Lewy bodies [30]. Cell counting was conducted on midfrontal cortex, cingulate, amygdala and hippocampus brain regions and in gray and white matter to determine if specific areas or matter type were specifically affected. These are summarized in Fig. 6. A one-way ANOVA was performed comparing the cell counts between AD and control tissue in different regions by tissue and matter type. The results of the interactions examined are shown in Table 3. Fig. 6A bar chart showing the range of cell counts in different brain regions in gray and white matter in control tissue and in AD tissue. WM white matter, GM gray matter, Cing cingulate, Amy amygdala, MFC midfrontal cortex, Hip hippocampus. Counts are shown as mean +/- SE, N = 6 in all cases
###end p 54
###begin p 55
###xml 2 11 2 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar chart</italic>
###xml 133 135 133 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">WM</italic>
###xml 150 152 150 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GM</italic>
###xml 166 170 166 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Cing</italic>
###xml 182 185 182 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Amy</italic>
###xml 196 199 196 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MFC</italic>
###xml 219 222 219 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Hip</italic>
###xml 269 270 267 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
A bar chart showing the range of cell counts in different brain regions in gray and white matter in control tissue and in AD tissue. WM white matter, GM gray matter, Cing cingulate, Amy amygdala, MFC midfrontal cortex, Hip hippocampus. Counts are shown as mean +/- SE, N = 6 in all cases
###end p 55
###begin title 56
Colocalization of peroxiredoxin 6 and AD pathology
###end title 56
###begin p 57
The major defining pathology in AD is the presence of extracellular plaques and intracellular hyperphosphorylated tau in the form of tangles. Plaques are present in brain tissue at different stages of development, ranging from diffuse plaques to fibrillar and neuritic plaques. It is generally considered that diffuse plaques do not contain tau, but neuritic plaques contain both Abeta and tau. Colocalization of peroxiredoxin 6 and the Abeta peptide, a major component of plaques, and tau was carried out to determine if peroxiredoxin 6 positive astrocytes were associated with AD pathology.
###end p 57
###begin title 58
Tau pathology
###end title 58
###begin p 59
###xml 188 189 188 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7</xref>
###xml 377 383 377 383 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;7</label>
###xml 383 386 383 386 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a&#8211;c</bold>
###xml 432 433 432 433 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 438 443 438 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 486 487 486 487 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 492 495 492 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 502 503 502 503 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 542 545 542 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar</italic>
###xml 557 560 556 559 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d&#8211;f</bold>
###xml 601 602 597 598 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 614 619 610 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 662 663 658 659 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 678 679 674 675 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 738 741 734 737 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar</italic>
###xml 753 756 748 751 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g&#8211;j</bold>
###xml 808 813 800 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 860 870 852 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">light blue</italic>
###xml 918 921 910 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar</italic>
###xml 933 934 924 925 <bold xmlns:xlink="http://www.w3.org/1999/xlink">k</bold>
###xml 1142 1148 1133 1139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arrows</italic>
###xml 383 1203 383 1194 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="60"><bold>a&#8211;c</bold> Confocal localization of tau within neurons (<bold>a</bold> Cy2-<italic>green</italic>) and peroxiredoxin 6 positive astrocytes (<bold>b</bold> Cy3-<italic>red</italic>) and (<bold>c</bold>) the merged image in AD brain tissue (<italic>bar</italic>&#160;=&#160;10&#160;&#956;M). <bold>d&#8211;f</bold> Confocal localization of A&#946; peptide (<bold>d</bold> Alexa 488, <italic>green</italic>) and peroxiredoxin 6 positive astrocytes (<bold>e</bold> Cy3-red) and (<bold>f</bold>) the merged image in a diffuse plaque in AD brain tissue (<italic>bar</italic>&#160;=&#160;50&#160;&#956;M). <bold>g&#8211;j</bold> Confocal localization of A&#946; peptide (Alexa 488, <italic>green</italic>) and peroxiredoxin 6 positive astrocytes (Cy5-<italic>light blue</italic>) in four different plaques in AD brain tissue (<italic>bar</italic>&#160;=&#160;50&#160;&#956;M). <bold>k</bold> Immunohistochemical staining (DAB substrate) showing peroxiredoxin 6 staining of astrocytes and astrocyte foot processes in the walls of blood vessels in the midfrontal cortex in Alzheimer&#8217;s disease (&#215;400). <italic>Arrows</italic> indicate peroxiredoxin 6 positive astrocytic processes</p>
###xml 383 1203 383 1194 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="60"><bold>a&#8211;c</bold> Confocal localization of tau within neurons (<bold>a</bold> Cy2-<italic>green</italic>) and peroxiredoxin 6 positive astrocytes (<bold>b</bold> Cy3-<italic>red</italic>) and (<bold>c</bold>) the merged image in AD brain tissue (<italic>bar</italic>&#160;=&#160;10&#160;&#956;M). <bold>d&#8211;f</bold> Confocal localization of A&#946; peptide (<bold>d</bold> Alexa 488, <italic>green</italic>) and peroxiredoxin 6 positive astrocytes (<bold>e</bold> Cy3-red) and (<bold>f</bold>) the merged image in a diffuse plaque in AD brain tissue (<italic>bar</italic>&#160;=&#160;50&#160;&#956;M). <bold>g&#8211;j</bold> Confocal localization of A&#946; peptide (Alexa 488, <italic>green</italic>) and peroxiredoxin 6 positive astrocytes (Cy5-<italic>light blue</italic>) in four different plaques in AD brain tissue (<italic>bar</italic>&#160;=&#160;50&#160;&#956;M). <bold>k</bold> Immunohistochemical staining (DAB substrate) showing peroxiredoxin 6 staining of astrocytes and astrocyte foot processes in the walls of blood vessels in the midfrontal cortex in Alzheimer&#8217;s disease (&#215;400). <italic>Arrows</italic> indicate peroxiredoxin 6 positive astrocytic processes</p></caption>
###xml 1203 1203 1194 1194 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="401_2008_373_Fig7_HTML" id="MO7"/>
###xml 377 1203 377 1194 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig7"><label>Fig.&#160;7</label><caption><p textid="60"><bold>a&#8211;c</bold> Confocal localization of tau within neurons (<bold>a</bold> Cy2-<italic>green</italic>) and peroxiredoxin 6 positive astrocytes (<bold>b</bold> Cy3-<italic>red</italic>) and (<bold>c</bold>) the merged image in AD brain tissue (<italic>bar</italic>&#160;=&#160;10&#160;&#956;M). <bold>d&#8211;f</bold> Confocal localization of A&#946; peptide (<bold>d</bold> Alexa 488, <italic>green</italic>) and peroxiredoxin 6 positive astrocytes (<bold>e</bold> Cy3-red) and (<bold>f</bold>) the merged image in a diffuse plaque in AD brain tissue (<italic>bar</italic>&#160;=&#160;50&#160;&#956;M). <bold>g&#8211;j</bold> Confocal localization of A&#946; peptide (Alexa 488, <italic>green</italic>) and peroxiredoxin 6 positive astrocytes (Cy5-<italic>light blue</italic>) in four different plaques in AD brain tissue (<italic>bar</italic>&#160;=&#160;50&#160;&#956;M). <bold>k</bold> Immunohistochemical staining (DAB substrate) showing peroxiredoxin 6 staining of astrocytes and astrocyte foot processes in the walls of blood vessels in the midfrontal cortex in Alzheimer&#8217;s disease (&#215;400). <italic>Arrows</italic> indicate peroxiredoxin 6 positive astrocytic processes</p></caption><graphic position="anchor" xlink:href="401_2008_373_Fig7_HTML" id="MO7"/></fig>
Tau deposits in the form of neurofibrillary tangles were observed in many neurons and neurites, and were often surrounded by peroxiredoxin 6 astrocytes, which made multiple contacts (Fig. 7a-c). Although astrocytes made many contacts with neurons, most neurons had very low levels of peroxiredoxin 6 and it did not appear to be upregulated or to be colocalized with tau in AD. Fig. 7a-c Confocal localization of tau within neurons (a Cy2-green) and peroxiredoxin 6 positive astrocytes (b Cy3-red) and (c) the merged image in AD brain tissue (bar = 10 muM). d-f Confocal localization of Abeta peptide (d Alexa 488, green) and peroxiredoxin 6 positive astrocytes (e Cy3-red) and (f) the merged image in a diffuse plaque in AD brain tissue (bar = 50 muM). g-j Confocal localization of Abeta peptide (Alexa 488, green) and peroxiredoxin 6 positive astrocytes (Cy5-light blue) in four different plaques in AD brain tissue (bar = 50 muM). k Immunohistochemical staining (DAB substrate) showing peroxiredoxin 6 staining of astrocytes and astrocyte foot processes in the walls of blood vessels in the midfrontal cortex in Alzheimer's disease (x400). Arrows indicate peroxiredoxin 6 positive astrocytic processes
###end p 59
###begin p 60
###xml 0 3 0 3 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a&#8211;c</bold>
###xml 49 50 49 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 103 104 103 104 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 109 112 109 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">red</italic>
###xml 119 120 119 120 <bold xmlns:xlink="http://www.w3.org/1999/xlink">c</bold>
###xml 159 162 159 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar</italic>
###xml 174 177 173 176 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d&#8211;f</bold>
###xml 218 219 214 215 <bold xmlns:xlink="http://www.w3.org/1999/xlink">d</bold>
###xml 231 236 227 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 279 280 275 276 <bold xmlns:xlink="http://www.w3.org/1999/xlink">e</bold>
###xml 295 296 291 292 <bold xmlns:xlink="http://www.w3.org/1999/xlink">f</bold>
###xml 355 358 351 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar</italic>
###xml 370 373 365 368 <bold xmlns:xlink="http://www.w3.org/1999/xlink">g&#8211;j</bold>
###xml 425 430 417 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">green</italic>
###xml 477 487 469 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">light blue</italic>
###xml 535 538 527 530 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bar</italic>
###xml 550 551 541 542 <bold xmlns:xlink="http://www.w3.org/1999/xlink">k</bold>
###xml 759 765 750 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arrows</italic>
a-c Confocal localization of tau within neurons (a Cy2-green) and peroxiredoxin 6 positive astrocytes (b Cy3-red) and (c) the merged image in AD brain tissue (bar = 10 muM). d-f Confocal localization of Abeta peptide (d Alexa 488, green) and peroxiredoxin 6 positive astrocytes (e Cy3-red) and (f) the merged image in a diffuse plaque in AD brain tissue (bar = 50 muM). g-j Confocal localization of Abeta peptide (Alexa 488, green) and peroxiredoxin 6 positive astrocytes (Cy5-light blue) in four different plaques in AD brain tissue (bar = 50 muM). k Immunohistochemical staining (DAB substrate) showing peroxiredoxin 6 staining of astrocytes and astrocyte foot processes in the walls of blood vessels in the midfrontal cortex in Alzheimer's disease (x400). Arrows indicate peroxiredoxin 6 positive astrocytic processes
###end p 60
###begin title 61
Plaques
###end title 61
###begin p 62
###xml 194 195 191 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7</xref>
###xml 469 470 466 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7</xref>
Diffuse plaques contained strongly stained aggregations of Abeta peptide. Peroxiredoxin 6 staining was confined to astrocytes and their projections that were in close proximity to plaques (Fig. 7d-h). Some astrocytes were observed within plaques, but generally the astrocyte cell bodies were on the periphery with their processes projecting into the plaques. Some plaques contained the beginnings of a dense core of amyloid and took on a "wagon wheel" appearance (Fig. 7i, j). Diffuse plaques and those with Abeta beginning to aggregate appeared to elicit a stronger peroxiredoxin 6 astrocytic response than those with a dense core of Abeta.
###end p 62
###begin title 63
Peroxiredoxin 6 staining of blood vessels
###end title 63
###begin p 64
###xml 218 219 218 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig7" ref-type="fig">7</xref>
In many regions of the AD brain, there appeared to be strong peroxiredoxin 6 staining in the walls of many blood vessels, which could be seen to have multiple contacts with strongly staining activated astrocytes (Fig. 7k).
###end p 64
###begin title 65
Discussion
###end title 65
###begin p 66
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 445 447 445 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 613 614 613 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
###xml 736 738 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 96 101 <span type="species:ncbi:9606">human</span>
###xml 883 888 <span type="species:ncbi:9606">human</span>
Peroxiredoxin 6, also known as 1-Cys peroxiredoxin or non-selenium glutathione peroxidase, is a human brain antioxidant enzyme that is abundant in activated astrocytes and present in low levels in neurons. On exposure to hydrogen peroxide, the N-terminal peroxiredoxin 6 corresponding to Cys 47 is readily oxidized, but as yet its redox partner has not been identified. Glutathione, lipoic acid and cyclophilin have all been implicated [13, 23, 29]. In addition to its peroxidase activity, peroxiredoxin 6 also has phospholipase A2 activity that might be significant in the brain, which has a high lipid content [9]. Peroxiredoxin 6 staining of astrocytes is markedly elevated in many brain regions in PD and dementia with Lewy bodies [30]. We now show that it is upregulated in the astrocytes in AD and describe for the first time the range of molecular forms of peroxiredoxin 6 in human brain in both control and AD tissue.
###end p 66
###begin p 67
###xml 680 682 680 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 1021 1023 1021 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 1025 1027 1025 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 1156 1158 1153 1155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 928 933 <span type="species:ncbi:10090">mouse</span>
###xml 947 952 <span type="species:ncbi:9606">human</span>
Three major variants and five minor forms were identified with pIs ranging from 5.3 to 6.1. There were three major differences in the peroxiredoxin 6 variants between control and AD tissue. The AD tissue had the two more acidic forms 1 and 2 that were not present in control tissue; the intensity of the major forms 6 and 7 were reversed between AD and control tissue and minor form 8 was absent in AD tissue. We can only speculate on the significance of these findings at this stage, but different forms may have different affinities for different substrates that might be more abundant under various pathological conditions or the more acidic forms are the result of oxidation [11]. At this stage, we cannot determine whether these differences are true isoforms or post-translational modifications of the same protein, but would suspect the latter. These findings are in agreement with two previous proteomic studies in an AD mouse model and in human brain AD tissue, which reported elevated levels of peroxiredoxin 6 [33, 34]. A more recent study using PC12-resistant and PC12 cells treated with Abeta also reported increased levels of peroxiredoxin 6 [11]. Abeta-treated cells contained an extra acidic form, which was suggested to be the result of oxidation of the catalytic cysteine to a sulfenic, sulfinic or sulfonic derivative. We found two minor acidic forms in AD tissue, which is also consistent with this report.
###end p 67
###begin p 68
###xml 235 241 <span type="species:ncbi:9606">people</span>
Tissue selection is also a variable that needs to be considered. While the AD tissue had all the hallmarks of AD pathology and was easy to define, age-matched control tissues are somewhat more variable. All the control tissue was from people without clinically defined AD, but most brains in this age group usually contain some neurodegenerative pathology. The age span of the two groups was similar, 59-84 years for the AD group and 61-86 years for the control group, but the mean age for the control group was 7 years older. We feel confident that, although some control tissue may have had some elements of subclinical AD pathology, the reduced level of astrocyte activation and the clear differences in the cell counting would indicate that all the control tissues were not experiencing high levels of oxidative stress as compared to the AD tissue.
###end p 68
###begin p 69
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
Previously, we had shown that peroxiredoxin 6 was abundant in astrocytes in PD and dementia with Lewy body tissue [30]. We have now used cellular markers to other brain cell types to show that in addition to astrocytes there is a low level in the cytoplasm of most neurons. Unlike astrocytes, neurons do not appear to have increased peroxiredoxin 6 staining in AD tissue. We could not detect any peroxiredoxin 6 staining in microglia or oligodendrocytes.
###end p 69
###begin p 70
###xml 337 338 337 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">F</italic>
Cell counting of peroxiredoxin 6 positive astrocytes indicated that there was a marked increase in both the gray and white matter in AD tissue compared with control tissue. Gray matter had more peroxiredoxin 6 positive astrocytes than white matter in both AD and control tissue, and this difference was more pronounced in AD tissue with F values of 89.0 and 14.5, respectively. Considering that the major pathology (plaques and tangles) is located in the gray matter, it would be expected that oxidative stress is more pronounced in this area. Cell counting indicated that the peroxiredoxin 6 positive astrocyte numbers were elevated in all regions examined, suggesting that the insult activating astrocytes is wide spread and not confined to any specific region in either the gray or white matter. Indeed, extracellular plaques were observed in all regions examined in AD tissue. Although all regions examined showed astrocyte activation, this was not uniformly distributed through all areas, with some areas showing extensive astrocyte activation while adjacent areas were similar to controls.
###end p 70
###begin p 71
###xml 177 179 174 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 303 305 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 307 309 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 417 419 414 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 421 423 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 507 509 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 919 920 904 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 1848 1850 1824 1826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
There are two defining pathologies in AD. These are the presence of extracellular plaques comprising abundant deposits of Abeta peptides, which later aggregate to form amyloid [25] and intracellular hyperphosphorylated tau aggregations in the form of paired helical filaments, which are termed tangles [14, 22]. The two well-described forms of plaques have been termed diffuse plaques and neuritic or senile plaques [12, 18], although other intermediate forms such as fibrillar plaques have been described [12]. Diffuse plaques are spherical structures of less dense Abeta deposits and are considered an early stage of plaque formation. In diffuse plaques, aggregations of Abeta exists as nonamyloid deposits, but as the plaque progresses, the Abeta and other protein aggregations change from the normal conformation into a beta-sheet structure, termed amyloid, and take up specific dyes like Congo red and thioflavin [4]. These plaques do not generally contain tau; however, in many confocal images, diffuse plaques contain focal points of tau, which are probably enlarged neurites. Neuritic or senile plaques contain a dense core of amyloid enriched with Abeta peptide with a corona of less dense amyloid. The diffuse plaques appeared to elicit a stronger astrocytic response based on the level of peroxiredoxin 6 staining than the neuritic plaques. Our images suggest that once the Abeta forms amyloid and condenses, it is less stimulating toward astrocytes and perhaps the formation of amyloid is a protective mechanism to inactivate the toxicity of soluble Abeta. These observations are consistent with the findings of Kawaguchi-Niida et al., who reported that the highly reactive carbonyl crotonaldehyde generated during lipid peroxidation is localized to reactive astrocytes, microglia and diffuse plaques but undetectable in amyloid cores [19].
###end p 71
###begin p 72
###xml 271 273 268 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
###xml 456 457 446 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
Although the activation of astrocytes and upregulation of peroxiredoxin 6 would be considered a protective response, in cell culture, soluble Abeta has been shown to stimulate nitric oxide synthetase and the production of nitric oxide, which is very damaging to neurons [17]. This response is further upregulated by other inflammatory cytokines such as interleukin 1beta and tumour necrosis factor-alpha, which are reported to be released from astrocytes [1]. At this stage, we are not sure of the net benefit to neural tissue of activated astrocytes with elevated levels of peroxiredoxin 6, concomitant with the increased production of nitric oxide.
###end p 72
###begin p 73
Neurofibrillary tangles comprising hyperphosphorylated tau were observed in many regions in AD tissue. Two antibodies were used to localize tau, a monoclonal antibody (Novacastra) and one specific for paired helical filaments (Santa Cruz) and both produced a similar staining pattern. Neurons containing tau were not surrounded by activated astrocytes as were the diffuse plaques and to a lesser extent the neuritic plaques, suggesting that these cells are not secreting toxic or activating products that are stimulating to astrocytes. In PD, Lewy bodies contained a dense core of peroxiredoxin 6 staining suggesting that it was trying to detoxify oxidative stress produced by Lewy bodies, but we did not observe any interaction between tau and peroxiredoxin 6 in AD tissue. Although there is considerable evidence to implicate oxidative stress in the hyperphosphorylation of tau, this does not appear to upregulate peroxiredoxin 6 in tau positive neurons.
###end p 73
###begin p 74
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 644 646 635 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 501 504 <span type="species:ncbi:10116">rat</span>
In some regions, the walls of blood vessels exhibited strong peroxiredoxin 6 staining, which also elicited a strong astrocytic response in surrounding astrocytes. These activated astrocytes had many processes in contact with the endothelial cells. Although vascular amyloid deposits were seen in some sections and is a key feature of AD [28], the upregulation of peroxiredoxin 6 appeared to occur in regions without distinct Abeta staining. Abeta has been shown to induce vascular vasoconstriction in rat skin, which can be reversed by superoxide dismutase and catalase, indicating that Abeta is capable of generating ROS within blood vessels [21]. The blood brain barrier consists of the capillary endothelial cells, and the foot processes of the astrocytes and the fused basal lamina of both cells. The peroxiredoxin 6 staining within the capillaries appears to be in the foot processes of the astrocytes. Whether this increased staining is due to ROS generated from within neural tissue or reflects a more systemic pathology derived from the circulation is unclear.
###end p 74
###begin p 75
###xml 152 157 <span type="species:ncbi:9606">human</span>
###xml 765 770 <span type="species:ncbi:9606">human</span>
In conclusion, we have shown for the first time the range of peroxiredoxin 6 variants, which are either isoforms or post-translational modifications in human brain tissue. We have also shown that peroxiredoxin 6 is primarily an astrocytic enzyme with very low levels in neurons and is not detectable in microglia or oligodendrocytes. This enzyme is markedly elevated in astrocytes in both white and gray matter in AD. Strongly staining peroxiredoxin 6 astrocytes appear to be involved in the detoxification of diffuse plaques and to a lesser extent in neuritic plaques, but is not associated with tau aggregations within neurons. From this work and previous work on PD and dementia with Lewy bodies, we suggest that peroxiredoxin 6 is a major antioxidant enzyme in human neural tissue.
###end p 75
###begin p 76
We gratefully acknowledge the excellent assistance of the Flinders University Proteomics Facility and the Flinders University Microscopy and Image Analysis Facility. This work was supported by the Flinders Medical Centre Foundation, Flinders University Faculty Grant and the National Health and Medical Research Council (Grant ID 275528).
###end p 76
###begin title 77
References
###end title 77
###begin article-title 78
beta-amyloid stimulation of inducible nitric oxide synthetase in astrocytes is interleukin-1beta and tumour necrosis factor-alpha (TNFalpha)-dependent, and involves a TNFalpha receptor-associated factor and NKFkappaB-inducing kinase-dependent signalling mechanism
###end article-title 78
###begin article-title 79
Overexpression of glutathione peroxidase increases the resistance of neuronal cells to Abeta-mediated neurotoxicity
###end article-title 79
###begin article-title 80
Oxidatively modified proteins in aging and disease
###end article-title 80
###begin article-title 81
Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs
###end article-title 81
###begin article-title 82
Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death
###end article-title 82
###begin article-title 83
Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress
###end article-title 83
###begin article-title 84
Modulation of phospholipid asymmetry in synaptosomal membranes by the lipid peroxidation products, 4-hydroxynonenal and acrolein: implications for Alzheimer's disease
###end article-title 84
###begin article-title 85
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Regional brain activity of free radical defence enzymes in autopsy samples from patients with Alzheimer's disease and nondemented controls
###end article-title 85
###begin article-title 86
###xml 90 91 90 91 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
1-Cys peroxiredoxin, a bifunctional enzyme with glutathione peroxidase and phospholipase A2 activities
###end article-title 86
###begin article-title 87
Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease
###end article-title 87
###begin article-title 88
Increase in expression levels and resistance to sulfhydryl oxidation of peroxiredoxin isoforms in amyloid beta-resistant nerve cells
###end article-title 88
###begin article-title 89
The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease
###end article-title 89
###begin article-title 90
Phospholipid hydroperoxides are substrates for non-selenium glutathione peroxidase
###end article-title 90
###begin article-title 91
Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology
###end article-title 91
###begin article-title 92
Evidence against the involvement of reactive oxygen species in the pathogenesis of neuronal death in Down's syndrome and Alzheimer's disease
###end article-title 92
###begin article-title 93
Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation
###end article-title 93
###begin article-title 94
Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release
###end article-title 94
###begin article-title 95
Confocal observation of senile plaques in Alzheimer's disease: senile plaque morphology and relationship between senile plaques and astrocytes
###end article-title 95
###begin article-title 96
Crotonaldehyde accumulates in glial cells of Alzheimer's disease brain
###end article-title 96
###begin article-title 97
Brain glutathione peroxidase in neurodegenerative disorders
###end article-title 97
###begin article-title 98
###xml 53 68 <span type="species:ncbi:10090">transgenic mice</span>
Mechanism of peripheral microvascular dysfunction in transgenic mice overexpressing the Alzheimer's disease amyloid Abeta protein
###end article-title 98
###begin article-title 99
Microtubule-associated protein tau (tau) is a major component of paired helical filaments in Alzheimer disease
###end article-title 99
###begin article-title 100
Cyclophilin A binds to peroxiredoxins and activates its peroxidase activity
###end article-title 100
###begin article-title 101
Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations
###end article-title 101
###begin article-title 102
Amyloid plaque core protein in Alzheimer's disease and Down syndrome
###end article-title 102
###begin article-title 103
###xml 82 90 <span type="species:ncbi:9606">patients</span>
Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients
###end article-title 103
###begin article-title 104
Increased expression but reduced activity of antioxidant enzymes in Alzheimer's disease
###end article-title 104
###begin article-title 105
Amyloid angiopathy of Alzheimer's disease: amino acid composition and partial sequence of a 4,200-dalton peptide isolated from cortical microvessels
###end article-title 105
###begin article-title 106
###xml 39 45 <span type="species:ncbi:9913">bovine</span>
Oxidation of active center cysteine of bovine 1-Cys peroxiredoxin to the cysteine sulfenic acid form by peroxide and peroxynitrite
###end article-title 106
###begin article-title 107
###xml 38 43 <span type="species:ncbi:9606">human</span>
Nonselenium glutathione peroxidase in human brain: elevated levels in Parkinson's disease and dementia with Lewy bodies
###end article-title 107
###begin article-title 108
###xml 59 62 <span type="species:ncbi:10116">rat</span>
Immunohistochemical localization and characterization of a rat Clara cell 26-kDa protein (CC26) with similarities to glutathione peroxidase and phospholipase A2
###end article-title 108
###begin article-title 109
###xml 48 53 <span type="species:ncbi:9606">human</span>
Lipid peroxidation products and antioxidants in human disease
###end article-title 109
###begin article-title 110
Proteomic analysis of the brain in Alzheimer's disease: molecular phenotype of a complex disease process
###end article-title 110
###begin article-title 111
###xml 63 68 <span type="species:ncbi:10090">mouse</span>
Proteomic analysis of brain tissue from an Alzheimer's disease mouse model by two-dimensional difference gel electrophoresis
###end article-title 111
###begin article-title 112
Chronological primacy of oxidative stress in Alzheimer's disease.
###end article-title 112
###begin article-title 113
Poole LB Structure, mechanism and regulation of peroxiredoxins
###end article-title 113

